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Multiple Sclerosis (MS) is an autoimmune disease characterized by the breakdown of 
immune tolerance towards autoantigen in the myelin sheath surrounding the neurons. Current 
therapies for MS and other autoimmune diseases focus on treating the symptoms and not the 
cause of the disease. A major setback in improving current therapeutics for autoimmunity is the 
lack of antigen specificity.  Successful antigen-specific immunotherapy (ASIT) would allow for 
improved treatment of autoimmune diseases. This thesis investigates the creation of ASIT for 
autoimmunity through the co-delivery of an immunomodulator and autoantigen.  First, 
immunomodulatory peptides targeting the B7 costimulatory pathway and cell adhesion were 
tested for their ability to suppress a murine model of MS, experimental autoimmune 
encephalomyelitis (EAE), utilizing a co-delivery vehicle developed in our lab, soluble antigen 
arrays. Peptides targeting different surface markers were all found to suppress EAE when co-
delivered with autoantigen, demonstrating the ability of different immunomodulators to create 
effective ASIT.  Expanding upon the idea of combinational ASIT, eleven different small 
molecules immunomodulators were screened for properties indicative of autoimmune 
suppression in an antigen-specific splenocyte system.  This screen revealed that several 
compounds, most notably dexamethasone, had the ability to skew the antigen-specific immune 
response towards autoimmune suppression.  The ability of dexamethasone to act as an effective 
immunomodulator in ASIT for autoimmunity was confirmed in vivo in the treatment of EAE.  
Co-delivery of dexamethasone and autoantigen in an oil-in-water emulsion, incomplete Freund’s 
adjuvant, was found to suppress EAE and shift the immune response.  Overall, the results 
presented dissertation provide evidence for the successful creation of ASIT for autoimmunity by 
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1. Introduction to Antigen-Specific Immunotherapy 
Antigen-specific immunotherapy (ASIT) has been used in the clinic for over a century to 
induce antigen-specific immune responses. Vaccines were the first modern successful antigen-
specific immunotherapies, utilizing disease-causing antigens in order to induce prophylactic 
protective immune responses against specific foreign pathogens. Treatments with specific 
allergy-inducing antigens have also been useful for the induction of antigen-specific immune 
tolerance for allergy desensitization.  Clinical treatment of autoimmune diseases, however, still 
relies primarily on global immune suppression through the use of potent small molecule 
immunomodulators. Within the last decade, scientists have begun to explore combinations of 
immunomodulators and autoantigens in the hope of creating effective ASIT for the treatment of 
autoimmune diseases; a strategy that could substantially improve clinical outcomes without 
compromising the entire immune system.   
One of the most successful strategies in ASIT for inducing immune tolerance has been the 
use of hyposensitization therapy in the treatment of allergies.  Hyposensitization therapy has 
been used since the early 1900s as a means to desensitize patients to specific allergens [1]. In the 
seminal papers published by Noon [2] and Freeman [3] in 1911, pollen extracts were injected 
subcutaneously using an increasing-dose schedule in order to relieve symptoms from grass 
pollen allergy and hay fever [1]. The current ‘gold standard’ for hyposensitization therapy is 
surprisingly similar to these techniques described over a century ago [1].  Although 
hyposensitization for allergies has been effective in many cases, several disadvantages have yet 
to be remedied.  The dosing schedule is often difficult for patients to complete due to the 
frequency and length of the therapy [1]. The majority of hyposensitization therapy is given via 




years [1, 4]. Sublingual ASIT may ultimately increase treatment convenience; however, the most 
important consideration, safety, may remain an issue [4].  Unfortunately, in some cases, 
hyposensitization therapy can become life threatening as anaphylaxis can occur following 
treatment of severe allergies, reinforcing the requirement for administration by a trained 
professional in a clinical setting [1].  Additionally, the mechanisms whereby hyposensitization 
therapy induces therapeutic immune tolerance or anaphylactic shock are still not completely 
understood [5].   
Using approaches similar to allergen immunotherapies, ASIT for the treatment of autoimmune 
diseases using only disease-causing autoantigen has been explored with minimal clinical success.  
Although these therapies often work in animal models; translation to humans has not shown the 
same level of efficacy [6-8]. Efforts to induce tolerance in autoimmune patients often use repeat 
administration of low doses of autoantigen or altered peptide ligands, but thus far, these approaches 
have suffered from poor long term clinical effectiveness and variable outcomes [6, 9, 10].  
Most of the currently approved autoimmune therapies are immunomodulators; the majority of 
these immunomodulators non-specifically cause immune suppression (i.e., immunosuppressants).  
As our understanding of immunology has improved, many therapeutic molecules once thought to 
act as specific immunosuppressants have recently been shown to have multiple mechanisms of 
action with numerous downstream effects.  For example, rapamycin (Sirolimus) has traditionally 
been considered an immunosuppressant drug; however, recently it has been discovered that the 
mammalian target of rapamycin (mTOR) pathway is essential in maintaining the balance between 
tolerance and inflammation [11]. Immunomodulation in the treatment of autoimmunity, therefore, 
extends far beyond immunosuppression and can involve shifting the immune response towards 




specificity in immunomodulation can lead to undesired side-effects and potentially increase the 
risk of opportunistic infections in patients taking these immunosuppressive therapies.  
One promising strategy in the creation of ASIT for autoimmunity is combination therapy of 
antigen and immunomodulator.  This strategy mimics the successful “antigen-adjuvant” model 
used in the creation of vaccines.  Adjuvants are immunomodulators used in vaccines to enhance 
the antigen-specific immune response, increasing the potency of the vaccine.  Applying this 
paradigm for treating autoimmune disease, the combination of antigen and immunomodulator may 
be able to direct the immune response toward tolerance to autoantigen. 
This review highlights recent work combining immunomodulators with autoantigen either by 
co-administration or co-delivery to induce tolerance in autoimmune disease.  We present a 
thorough background on the immunological processes involved in autoimmunity and tolerance, 
along with an examination of currently approved therapies.  Recent experimental work utilizing 
co-administration and co-delivery techniques, combining antigen and immunomodulator, have 
shown exciting new promise in autoimmune therapy.  ASIT combination therapies have also 
shown promise in the clinic. With the recent advances in ASIT, the potential to induce antigen-
specific tolerance to treat, prevent, or possibly cure a subset of autoimmune diseases in humans 
may be on the horizon. 
 
2. Introduction to Autoimmune Diseases 
2.1. Immune tolerance and Regulatory Responses  
The protective response of the immune system is deeply rooted in the selective recognition of 
foreign substances, or non-self-antigens, and the absence of a reaction to native antigens; the latter 




result in an immune response directed towards ‘self’ and is defined as an autoimmune response.  
While the origin of many autoimmune diseases still remains unclear, it is thought that a lapse in 
tolerance to autoantigens is a key step in the progression of the autoimmune response [12].  In 
order to understand how autoimmune diseases may develop in an individual, it is important to first 
assess the ways in which the body maintains tolerance toward autoantigens. The processes through 
which the immune system attempts to achieve and maintain tolerance toward autoantigens can be 
classified into two categories: central and peripheral.   
Central tolerance involves the presentation of autoantigen to T-cells and B-cells in the thymus 
and bone marrow.  This process is commonly referred to as negative selection and includes 
inducing apoptosis in developing lymphocytes which may recognize autoantigens or preventing 
their expansion and release into systemic circulation. Inevitably, some lymphocytes that recognize 
autoantigens are able to bypass the mechanism of central tolerance [13]. Fortunately, the immune 
system contains a variety of mechanisms to prevent activation of these potentially auto-reactive 
lymphocytes in peripheral tissue, known as peripheral tolerance.  These mechanisms include 
physical separation of auto-reactive T-cells from cells presenting autoantigens via the major 
histocompatibility complex (MHC) [14, 15]. Naïve T-cells are contained primarily to lymphoid 
peripheral tissues and blood, and as a result their encounters with autoantigen presentation by non-
lymphoid tissue cells are limited in healthy individuals [14].  In addition to antigen presentation 
via MHC restriction, T-cell activation requires the presence of surface expressed secondary context 
signaling (co-stimulatory) receptors, examples include CD80 (B7-1), CD86 (B7-2), CD40L, CD70, 
OX40L, and many others [16, 17].  Failure to provide the appropriate stimulatory context signals 
may result in functional inactivation of the lymphocyte, known as anergy. Besides these co-




cells, also known as ‘co-inhibitory’ receptors, and include cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) and programmed death-1 (PD-1) [16]. Ligation of these receptors has been 
shown to inhibit T-cell activation [18]. Conversely, mice lacking the co-inhibitory receptor CTLA-
4 develop lymphoproliferative disorders leading to death, suggesting a highly dependent 
regulatory component of these receptors [19]. The combination of these factors help support 
peripheral tolerance to maintain T-cell-dependent self-tolerance.     
The immune system also regulates antigen presentation in order to control peripheral T-cell 
responses.  In the periphery, antigen presenting cells (APCs), particularly dendritic cells (DCs), 
are major contributors to the initiation and regulation of downstream immune responses.  In 
addition to antigen uptake, processing, and presentation capability, DCs express a variety of co-
stimulatory and co-inhibitory receptors and are responsive to their local external environment.  For 
example, DCs can respond to signals elicited by pattern recognition receptors (PRRs) binding 
pathogen associated molecular patterns (PAMPs) [20].  Encounters with many PAMPs can result 
in up-regulation of co-stimulatory surface receptors, overexpression of MHC, and secretion of 
inflammatory cytokines; a microenvironment that can stimulate activation of naïve T-cells [20, 
21]. It is important to note that in the absence of these inflammatory signals, immature DCs can 
present antigen and induce tolerance in naïve T-cells, providing another means for regulation of 
autoimmune responses [14]. 
A third mechanism of peripheral tolerance is the presence of regulatory T-cells (Tregs).  Tregs 
suppress immune responses in an antigen-specific manner through cytokine secretion, metabolic 
disruption, and alteration of DC function [22].  It has been shown that secretion of cytokines such 
as interleukin (IL)-10, transforming growth factor (TGF)-β, and IL-35 play a role in the 




function of Tregs is still a point of debate [22]. Furthermore, it is hypothesized that Treg 
populations are capable of inducing apoptosis through deprivation of IL-2, a pro-inflammatory 
cytokine, due to the high expression of CD25, although the mechanisms are still not yet understood 
[22]. In addition to the previously mentioned influences on the local environment, it is believed 
that regulatory T-cells also act to alter the function of DCs upon antigen-MHC recognition and 
CTLA-4 ligation.  Studies indicate that Tregs are capable of up-regulating the expression of 
indoleamine 2, 3-dioxygenase (IDO) in DCs, an enzyme that has been found to limit the 
inflammatory response and induce a tolerogenic response [23].  Additionally, studies have 
indicated that Treg interactions with DCs may downregulate the expression of B7 (CD80/CD86) 
limiting DC function in activating T-cells [22]. 
2.2 Immunology of Autoimmunity  
In general, autoimmune diseases develop upon failure of the numerous regulatory pathways 
mentioned previously; however, ongoing studies are continuously evaluating and exploring new 
mechanisms whereby self-tolerance is disrupted.  Breakdown of tolerance toward autoantigen is 
often thought to be a result of both genetic and environmental risk factors, including exposure to 
infection by particular pathogens [24].  Multiple hypotheses have been generated to explain the 
downstream processes by which immune responses against autoantigen may occur upon exposure 
to an infectious pathogen including molecular mimicry of endogenous protein antigens, epitope 
spreading, and bystander activation; however, the exact mechanisms whereby autoimmune disease 
develops are still not well understood [24]. 
2.3 Autoimmune Diseases 
There are currently over 80 autoimmune diseases identified by the National Institute of Allergy 




most common autoimmune diseases include type 1 diabetes (T1D), rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), inflammatory bowel disease, psoriasis, and multiple 
sclerosis (MS). The discovery of a disease causing antigen or epitope is vital to the development 
of ASIT for autoimmunity; however, identifying such antigens is not a simple task, particularly in 
systemic autoimmune diseases such as SLE, for which there may be multiple antigenic targets 
[26].  The majority of current research in ASIT is focused on RA, T1D, and MS as they all have 
robust animal models, allowing for a greater understanding of autoimmune pathogenesis and the 
identification of disease-causing autoantigens.  
RA is typified by infiltration of the synovium by CD4+ T-cells, B-cells, and macrophages 
resulting in inflammation in joints.  In recent years, the focus of RA pathogenesis has shifted to 
the study of autoantibodies including anti-IgG rheumatoid factors (RFs) and anti-citrullinated 
protein antibodies (ACPAs), as these autoantibodies have been found to reliably predict disease 
progression [27]. Further research is required to determine the relevance of these autoantibodies 
and others to subsets of RA patients and disease progression.   
Recently, disease-specific targets for the treatment of T1D have also been identified including 
preproinsulin (PPI), glutamic acid decarboxylase (GAD65), and heat shock protein 60 (HSP60) 
[28]. T1D involves the destruction of insulin-producing pancreatic β-cells, resulting in the loss of 
the body’s ability to produce insulin and failure to control blood glucose levels. As such, clinical 
studies are commonly performed in early onset T1D patients in order to retain β-cell function and 
provide the greatest benefit to the patient.  Each of these antigens has been identified to play a role 
in the non-obese diabetic (NOD) mouse model for T1D and have recently been explored in clinical 




Similarly, potential disease causing autoantigens have been identified in MS including myelin 
basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP), and 
myelin associated glycoprotein (MAG) [32].  MS is characterized by inflammation of the central 
nervous system (CNS) due to immune cell mediated degradation of myelin proteins, resulting in 
neurological complications.  In the most common form of MS, symptoms follow a relapsing-
remitting form, and these symptoms may vary from one relapse period to another depending upon 
the location of the CNS inflammation [33]. A commonly employed animal model for MS is 
experimental autoimmune encephalomyelitis (EAE), which is usually induced in healthy mice by 
vaccination with MBP, MOG, or PLP autoantigens, allowing for insight into the pathogenesis of 
demyelinating autoimmune diseases [34]. 
 
3 Current therapies for autoimmunity 
Although autoimmune diseases are diverse in both cause and progression, most of the current 
therapies fall into a few distinct categories; general immunosuppressants, mobility and transport 
inhibitors, immune cell activation inhibitors, and antigen mimics (shown in Figure 1).  The 
downfall of the majority of current autoimmune therapies is the lack of antigen specificity. Many 
therapies inhibit or modify the global immune response hindering the patient’s ability to fight off 
foreign pathogens.  In order to decrease unwanted side effects and increase efficacy, treatments 
that induce antigen-specific tolerance are needed for autoimmune diseases. Recent advances in 





3.1 General Immunosuppressants 
Autoimmune diseases have traditionally used immunosuppressant medications that globally 
suppress the immune response.  Immunosuppressants are highly effective for many patients and 
therefore remain the current “gold standard” of autoimmunity treatment [35]. In many 
immunosuppressant therapies the benefits can be counterbalanced by toxicity or severe adverse 
events.  In fact, current treatments for the autoimmune disease RA fail in up to 50% of patients 
due to adverse side effects [36]. 
Immunosuppressants used in autoimmune treatment consist of both small molecules and 
biologics, such as proteins and antibodies, and can elicit their effect through several different 
mechanisms. Many anti-inflammatory compounds act by inhibition of immune cell proliferation, 
such as lefunomide (Arava) for RA and teriflunomide (Aubagio) for MS, which block synthesis 
of DNA necessary for cell division [37]. Chemotherapeutics including mitoxantrone (Novantrone) 
and methotrexate have also been used in treating autoimmunity due to their ability to inhibit DNA 
synthesis [37, 38].  Inhibition of cellular proliferation inhibits the rapid expansion of autoreactive 
immune cells that can cause tissue damage and further inflammation thereby reducing disease 
symptoms.  
Another common mechanism whereby immunosuppressant drugs act is via control of the 
cytokine response. Cytokines act as soluble messengers of the immune system; creating 
inflammatory or tolerogenic responses depending on the type and quantity of cytokines that are 
secreted in the local microenvironment.  Autoimmune therapies have tried to leverage the 
complexity of the cytokine response by inhibiting the production and action of pro-inflammatory 
cytokines.  Small molecule immunosuppressant compounds such as ciclosporin, used in the 




IL-2 is produced [38]. Additionally, several different biologics inhibiting cytokine binding are 
approved for use to treat RA including tocilizumab (Actemra) and etancercept (Enbrel), which 
inhibit pro-inflammatory cytokine signaling by IL-6 and tumor necrosis factor (TNF)-α, 
respectively [38, 39].  In the treatment of MS, interferon (IFN)-β therapy has been shown to 
decrease IFN-γ production through induction of neutralizing antibodies which help to decrease 
relapse rates in relapsing-remitting MS [37].  Although cytokine-targeted therapies have had 
successes in the clinic, the fact remains that cytokines are important in protection against invading 
pathogens, thus disruption of cytokine production or action can increase susceptibility to infection 
[12].  
The mechanisms for many immunosuppressants currently used to treat autoimmunity are not 
well understood.  Glucocorticoids, mainly prednisone and prednisolone, are commonly given to 
patients with SLE and RA.  These drugs have been shown to have numerous pleiotropic 
immunosuppressant effects, but may act somewhat by their ability to reduce the expression of 
cellular receptors needed for robust immune responses [40]. Dimethyl fumarate (Tecfidera) was 
approved by the FDA for treatment of MS in 2013 and is believed to work by preventing oxidative 
stress via activation of the Nrf2 transcriptional pathway; however, its influence on the immune 
response is still debated [37, 41].  
Unfortunately, a common theme among all immunosuppressants is their lack of specificity.  
These therapies must often be used long-term in order to suppress the immune response to self and 
do not cure the underlying disease condition, but rather mitigate symptoms by reducing tissue 
damage and inflammation. Due to their long term use and lack of specificity, severe toxicity issues 




3.2 Mobility and Transport Inhibitors 
Autoimmune diseases require the mobility of auto-reactive immune cells or antibodies to 
migrate to their site of action.  Mobility and transport inhibitors attempt to prevent this process.    
Similar to general anti-inflammatory molecules, severe side effects are often associated with 
these therapies, as they can restrict the movement of immune cells that are necessary to fight off 
foreign pathogens.  One such therapy, natalizumab (Tysabri), is a humanized antibody targeting 
vascular cell adhesion molecule-1 (VCAM-1) for the treatment of MS. Natalizumab reduces 
leukocyte trafficking across the blood brain barrier by inhibiting binding to the necessary cell 
adhesion molecules, thereby decreasing the number of auto-reactive T-cells in the CNS tissue 
[43].  Unfortunately, soon after it was approved by the FDA in 2004, natalizumab was found to 
be associated with an increased incidence of progressive multifocal myeloencephalopathy 
(PML), a fatal viral disease of the CNS [44].  It was found that there were several risk factors 
associated with PML, most notably the presence of JC virus antibodies in MS patients.  Upon 
implementation of PML risk mitigation strategies, including testing for JC virus antibodies 
before beginning therapy, natalizumab was reapproved in 2006 for MS patients un-responsive to 
other therapies [44].  Another mobility blocking therapy, efalizumab (Raptiva), an anti-LFA-1 
antibody, met with a similar fate as natalizumab.  Efalizumab was found to reduce the severity of 
chronic psoriasis, an autoimmune disease of the skin, but it was withdrawn from clinical use in 
all cases after several PML cases in patients [16].  
Another FDA approved drug, fingolimod (Gilenya) is a small molecule mobility inhibitor 
used for the treatment of MS. Fingolimod acts by internalization of S1P-receptors on immune 
cells to prevent them from egressing from lymph nodes and trafficking to the CNS [37]. Unlike 




be used in patients that test positive for the JC virus.  Nevertheless, mobility and transport 
inhibitors are often not prescribed until an MS patient presents with aggressive disease and CNS 
lesions [37]. 
3.3 Immune cell activiation inhibitors 
As previously discussed, both antigen presentation and a co-stimulatory context signal are 
needed to activate immune cells in an antigen-specific immune response.  Recent evidence 
suggests that a change or lack of co-stimulation can prevent immune activation and even skew 
the response towards tolerance [16, 45, 46].    Due to the importance of co-stimulation in 
directing the antigen-specific immune response, several co-stimulatory pathways have been 
investigated in the induction of tolerance and treatment of autoimmunity.  
The B7 (CD80/86) signaling pathway is one of the most well-characterized co-stimulatory 
pathways in T-cell activation and has therefore been a major target in T-cell mediated 
autoimmune diseases.  The B7 pathway consists of two main molecular interactions, B7:CD28 
binding leading to immune-stimulation and B7: CTLA-4 binding leading to immunosuppression 
or tolerance to the presented antigen [47].  Since CTLA-4 acts as a co-inhibitory signal in T-cell 
activation it has been the key focus in targeting the B7 pathway for autoimmune therapy. Three 
immunomodulatory biologics approved by the FDA in the past 10 years either target or are 
derived from CTLA-4; with two primarily used in the treatment of autoimmunity [48].  
Abatacept (Orencia), a CTLA-4 IgG1 fusion protein, was the first biologic targeting the B7 
pathway approved to treat autoimmunity.  It was initially approved to treat RA in 2005, and is 
currently under investigation in the treatment of other T-cell mediated autoimmune diseases 
including T1D, psoriasis, and SLE [48].  Another CTLA-4 IgG1 fusion protein, belatacept 




was approved to treat organ transplant rejection in 2011 and is currently in clinical trials for the 
treatment of RA and T1D [48]. Although these B7 pathway inhibitors show promise in the 
treatment of autoimmunity, they are not antigen-specific in their immune modulation.   
Several other therapies target cell surface markers involved in activation of the immune 
response.  Alemtuzumab (Lemtrada) is an anti-CD52 antibody approved for the treatment of MS 
[37, 39].  CD52 is found on a variety of immune cells and, although its exact function is still 
unknown, it is believed to be involved in co-stimulation as its cross-linking leads in T-cell 
activation [37]. Another antibody targeting T-cell receptors, daclizumab (Zenapex) is approved 
to prevent organ transplant rejection and is currently under investigation as a treatment for MS.  
Daclizumab binds to CD25, which is expressed on activated T-cells and Tregs.  Ongoing phase 
III clinical studies indicate that in addition to blocking T-cell activation, daclizumab also works 
to expand regulatory natural killer (NK) cells to treat MS [49].  
In addition to targeting T-cell activation, with our increasing understanding of the role of B-
cells in autoimmunity, there has been investigation into the use of B-cell targeted therapies in the 
treatment of autoimmune diseases such as RA, MS, and SLE.  Rituximab (Rituxan), a chimeric 
IgG1 anti-CD20 monoclonal antibody, is often administered alongside methotrexate to RA 
patients who are unresponsive to more common treatments such as anti-TNF agents [50].  
Rituximab has also been successful in clinical trials investigating the effectiveness of B-cell 
depletion in the treatment of MS [51] and SLE [52].  Recently, other human antibodies targeting 
CD20 such as ocrelizumab, veltuzumab, ofatumumab, and TRU015 have been clinically 




3.4 Antigen Mimics 
Use of antigen mimics, or “decoys”, is a strategy aimed at inducing an antigen-specific 
immune response while avoiding potential anaphlaxysis that may be associated with the native 
antigen.  Insulin and insulin analogues used in the treatment of T1D are some of the most widely 
used antigen mimics for autoimmune therapy; however, until just recently insulin was considered 
a hormonal therapy that had little to no effect on the immune response. Recent evidence 
suggesting that insulin is the initiating antigen in the development of T1D has led researchers to 
revisit insulin therapy [54]. Although better understanding of the immune response offers the 
potential to enhance T1D treatment, so far clinical trials have failed to improve upon current 
insulin therapy [54]. 
Another form of antigen mimics, altered peptide ligands (APLs), are created through 
substituting different amino acid for those in the antigenic epitope.  APLs of antigenic epitopes 
in MBP with varying affinity for MHC class II molecules have been synthesized and studied for 
the induction of immune tolerance to treat EAE.  Results indicate a correlation between APL 
affinity for MHC class II molecules and EAE disease prevention, with APLs of higher affinity 
displaying a shift in cytokine secretion toward IL-10 and greater suppression of T-cell 
proliferation [55]. Due to the heterogeneity of the antigen-specific T-cell populations involved in 
an autoimmune response, it may be necessary to design an APL capable of inducing tolerance 
across a wide range of T-cell receptor (TCR) affinities in order to produce a lasting effect [56, 
57].  
Glatiramer acetate (Copaxone) is an altered polymeric version of the MS-associated antigen 
MBP.  Many immunomodulatory mechanisms have been proposed for glatiramer acetate 




immune response, and TCR antagonism in MBP-specific T-cells [57, 58]. The multiple 
mechanism of action would suggest that glatiramer acetate may act through both antigen-specific 
and non-specific pathways to alter autoimmune responses; however, further studies are required 
to determine the relevance of each of these mechanisms.   
3.5 Current combination therapies for autoimmune disease  
In many cases, combinations of drugs from the therapeutic categories discussed previously 
are used in order to enhance efficacy.  In RA, a small molecule immunosuppressant, 
methotrexate, is often prescribed with TNF-α inhibitor therapy in order to achieve a synergistic 
effect [38].  This synergistic effect is not found in all combinations of therapies utilizing two 
biologics. For example, a TNF-α inhibitor and co-stimulation inhibitor, abatacept, did not 
achieve additional clinical benefits in the treatment of RA, but rather caused toxicity from 
immunosuppression complications [38]. Although this combination approach has shown 
promise, it is still missing the antigen specificity needed to reduce side effects and increase long 
term efficacy.   
 
4 Combination strategies for ASIT in autoimmunity 
With the clinical failure of many antigen-only therapies for autoimmunity, recent research 
has focused on combination therapy containing antigen and immunomodulator to enhance 
efficacy.  Combination therapy can be accomplished by either co-administration (dosing in a 
similar time-frame, often via the same route) or co-delivery (utilizing a vehicle to physically or 
chemically keep the antigen and immunomodulatory in close physical proximity) (Table 2 and 




treatment autoimmunity, it may be possible skew the immune response towards antigen-specific 
tolerance.   
4.1 Co-Administration 
Many of the initial studies done with antigen and immunomodulators in the early to mid-
2000s utilized co-administration to create ASIT combination therapy (Table 3).  Dosing antigen 
and immunomodulator together without a co-delivery vehicle offers the flexibility of delivering 
the compounds via different routes.  Also, the lack of a vehicle needed to co-encapsulate or 
connect the components may be more economically feasible and allow for ease of manufacturing 
and formulation; factors that may help accelerate the transition into to the clinic.  Using co-
administration in ASIT also has the disadvantage of producing similar side-effects as many 
current therapies; since when the antigen and immunomodulator are separated the 
immunomodulator may produce a general immunosuppressive response rather than an antigen-
specific response. 
4.1.1 Co-Administration with small molecule immunosuppressants 
Small molecule immunosuppressants are commonly prescribed for autoimmune disease 
treatment.  In order to reduce global immunosuppression, recent studies have investigated the co-
injection of autoantigen, or DNA encoding autoantigen, simultaneously with a small molecule 
immunosuppressant.  Kang and colleagues pioneered the use of the term ‘tolerogenic adjuvant’ 
in their 2008 paper involving the co-administration of dexamethasone and autoantigen to induce 
antigen-specific tolerance in a model of autoimmunity [59]. Co-injection of dexamethasone and 
OVA resulted in long-term antigen-specific tolerance as well as the proliferation of OVA-
specific regulatory T cells.   Similar antigen-specific tolerogenic responses were also seen using 




injection of a different ‘tolerogenic adjuvant’, the immunosuppressant FK-506 (Tacrolimus), 
with a plasmid DNA encoding autoantigen, rather than the antigen itself, also results in 
expansion of Tregs and suppression of autoimmunity in mice [60]. 
4.1.2 Co-Administration with Biological Molecules  
Unlike the monoclonal antibodies that dominate the clinically-approved biologics for 
autoimmunity, the majority of co-administration research for ASIT has focused on the use of 
plasmid DNA as the biological delivery platform.  Co-administration of plasmid DNA encoding 
autoantigen and a plasmid containing immunomodulatory gene have been studied by several 
research groups.  The injection of two plasmids, with autoantigen on one and immunomodulator 
on the other, classify these studies as co-administration rather than co-delivery. 
In 2001, Garren and colleagues published a paper examining DNA vaccination using two 
plasmids, one encoded with interleukin (IL)-4, a cytokine associated with immunosuppression in 
MS, and the second encoded with a MS-associated autoantigen [61]. The co-vaccination strategy 
was tested in EAE mice with both PLP and MOG-induced models.  In both models, co-
administration of IL-4 and autoantigen encoding plasmids was found to suppress EAE disease 
compared to treatment with each gene individually.  Interestingly, the MOG and IL-4 DNA 
vaccination was able to reverse established disease when given after EAE symptoms were 
present [61]. In a similar study, Glinka and colleagues investigated the use of DNA vaccination 
to co-administer autoantigen and a co-stimulation blocker for the treatment of NOD mice [62].  
The study used a plasmid encoding for a fusion construct of PPI and GAD65 for induction of 
autoantigen expression, along with a plasmid encoding a mutant B7 molecule known to bind 




decreasing disease symptoms and stimulating the tolerogenic response following co-
administration of the plasmids [62]. 
Although co-administration of DNA has been successful in animal models, it is difficult to 
control dosage kinetics and gene expression, limiting its clinical potential. The combination of 
protein immunomodulators with antigens has gained interest for easier clinical translation. In a 
recent study, MOG35-55 and the tolerogenic cytokine IL-10 were encapsulated into separate 
PLGA nanoparticles for the treatment of EAE [63]. Both prophylactic and therapeutic treatment 
regimens co-administering particles containing MOG and particles containing IL-10 significantly 
suppressed EAE symptoms [63]. Using a similar strategy, Lewis and colleagues created PLGA 
microparticles each containing a single component; insulin B autoantigen, GM-CSF, vitamin D3, 
or TGF-β1.  When these 4 different microparticles were mixed at a 1:1:1:1 ratio they were found 
to significantly prevent the incidence of T1D in NOD mice [64]. These successful experimental 
studies suggest the feasibility of a prophylactic or therapeutic co-administration platform to treat 
autoimmune disease. 
4.1.3 Drawbacks of Co-Administration  
While the co-administration approach has shown potential in animal models of 
autoimmunity, the lack of a formulation keeping the autoantigen and immunomodulator in the 
same microenvironment opens the door for non-specific immunosuppression or complete lack of 
efficacy upon separation of the components following dose administration.  In fact, not 
delivering antigen and immunomodulator together both temporally and spatially can result in 
induction of an inflammatory response rather than a tolerogenic response.  In a recent study, it 




immunosuppressant, resulted in expansion of autoantigen-specific T-cells and inhibition of 
Tregs, the opposite of the desired tolerogenic response [65].  
4.2 Co-delivery 
Unlike co-administration, co-delivery ensures that the antigen and immunomodulator are 
delivered at the same time and presented in the same environment to auto-reactive immune cells 
(Table 2).  Many investigators have examined the effect of delivering encapsulated 
immunomodulators or autoantigen alone for autoimmune therapy [66-70]; however, only 
recently have studies focused on the effect of co-delivering these components via a variety of 
different delivery vehicles (Table 4 and Figure 2). 
4.2.1 Co-Delivery with small-molecule immunosuppressants  
Building upon previous literature using co-administration of autoantigen and small-molecule 
immunosuppressant, several research groups have investigated the possibility of co-delivering 
these components.  Various delivery vehicles have been employed with results that suggest 
dosing compounds together both spatially and temporally may enhance treatment efficacy.  
Liposomes, dextran microparticles, and gold and PLGA nanoparticles have all been used in 
recent studies in order to co-deliver autoantigen and immunosuppressant for ASIT in animal 
models of autoimmunity [65, 71-73].  In each of these examples, the two components were either 
co-encapsulated or co-adsorbed to the delivery vehicle to ensure simultaneous delivery of the 
components to immune cells [65, 71-73]. 
Peine and colleagues extrapolated work by Kang and colleagues by co-encapsulating 
autoantigen and dexamethasone in microparticles [59, 71]. Dexamethasone was co-encapsulated 
into acid-sensitive acetylated dextran microparticles with the MS-antigen MOG and used in the 




score as compared to mixtures of dexamethasone and MOG, demonstrating the importance of 
delivering both components concurrently to immune cells [71]. 
Yeste and colleagues investigated co-delivery of MOG and the small molecule 
immunosuppressant 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) 
[72].  Both MOG and ITE were co-loaded onto the outside of gold nanoparticles and were found 
to induce tolerogenic DCs and FoxP3+ Tregs in naïve primary cells.  The nanoparticles 
significantly suppressed EAE disease symptoms as compared to the components given without 
use of the co-delivery vehicle [72].  In a unique experiment, Yeste and colleagues also 
demonstrated that their co-delivery system was effective even after epitope spreading, by 
utilizing two different epitopes of autoantigen to suppress EAE [72]. Using a similar approach, 
Maldonado and colleagues delivered both autoantigen and rapamycin co-encapsulated in PLGA 
nanoparticles to treat a number of autoimmune models [65].  The antigen-rapamycin 
nanoparticles were able to induce antigen-specific tolerance in EAE, in a model of 
hypersensitivity, and in a model of the genetic disease hemophilia [65].    In both studies 
encapsulating the immunosuppressant alone was found to suppress disease; however, the 
autoantigen-containing nanoparticle did not [65, 72]. 
In addition to the possible use of different types of delivery vehicles to produce antigen-
specific tolerance, Capini and colleagues demonstrated that different immunosuppressant drugs 
could also be effective [73]. Their study examined the effects of three different NF-κB inhibitors; 
curcumin, quercetin, and Bay11-7082.  When co-encapsulated into liposomes with autoantigen 
each of the three compounds were able to induce antigen-specific Treg responses and decrease 




4.2.2 Co-Delivery with Peptides  
Peptides targeting immune cell adhesion or co-stimulation molecules have been conjugated 
with autoantigen epitopes to enable co-delivery. Siahaan and colleagues have published a 
number of papers on bi-functional peptide inhibitors (BPI) that link a peptide autoantigen with an 
immune cell inhibitor targeting the cell adhesion molecule ICAM-1.  BPIs have suppressed 
disease in animal models of both T1D and MS [74, 75].  The originally developed BPI co-
delivery vehicle contained the MS epitope PLP139-151 linked to the peptide LABL, derived from 
αL integrin, for the treatment of EAE. This unique ASIT was found to significantly decrease the 
severity of EAE disease as compared to each peptide alone or mixed [75, 76].  Interestingly, the 
BPI decreased the rate of anaphylaxis in mice as compared to PLP alone, suggesting that 
autoimmune treatments containing immunomodulators may offer improved safety as compared 
to autoantigen alone [75].   
Building off of Siahaan’s work, Berkland and colleagues have published several papers on a 
multivalent approach known as a Soluble Antigen Arrays (SAgAs).  SAgAs consist of antigenic 
peptides and immunomodulator peptides that are co-delivered via a hyaluronic acid backbone. 
Peptides inhibiting cell adhesion (via ICAM-1) and the B7 (CD80/CD86) pathway have shown 
efficacy in EAE when co-delivered with MS antigen using SAgAs [77]. 
4.2.3 Co-Delivery with Biological Molecules 
As previously discussed, DNA vaccines have successfully co-administered two plasmids, 
separate autoantigen and immunomodulator, to treat autoimmunity.  In attempt to improve upon 
this technique, autoantigen and immunomodulator were encoded on a single plasmid.  A couple 
of recent studies investigated this strategy for the treatment of TID in NOD mice with plasmids 




BAX, respectively [78, 79].  In both studies, the plasmid containing both autoantigen and 
immunomodulator were able to prevent and suppress disease [78, 79]. 
Another study utilized the co-delivery of a plasmid encoding the B and T lymphocyte 
attenuator protein (BTLA) and MOG antigen to pre-treat DCs before using those DCs to treat 
EAE mice [80].  These pre-treated DCs were found to decrease the severity of EAE when 
injected prophylactically; however, this approach may be too complex for clinical application 
[80]. 
 
5 Clinical Trials of ASIT for Autoimmunity 
5.1 Antigen-only ASIT Clinical Trials 
Similar to allergy hyposensitization, the introduction of a disease-causing autoantigen to a 
patient with autoimmunity can result in undesired and potentially life threatening adverse events 
[81, 82].  A Phase II clinical study of an altered peptide ligand of MBP, an antigen associated with 
MS, had to be halted due to three of the eight patients suffering worsening symptoms, resulting in 
an increase in CNS lesions up to 2.4 times the amount before therapy and leaving one patient 
unable to walk.  In other cases, administration of a slightly altered autoantigen to treat 
autoimmunity did not directly aggravate the disease but instead resulted in an allergic response to 
the antigen [82]. Fortunately, in the majority of clinical trials these adverse events were avoided; 
however, ASIT did not result in any benefit compared to placebo [83]. 
5.2 Combination ASIT Clinical Trials 
Recently, trials of combinations of antigen and immunomodulator for ASIT have shown 
promise. In several clinical studies for MS, the FDA approved drug glatiramer acetate (GA) was 




immunomodulators to study the effects of combination therapy. In one study improved success in 
both decreasing CNS symptoms and lowering the risk of disease relapse was seen in combination 
of GA and the antibiotic minocycline, as compared to GA alone [84].  In another study, GA and 
natalizumab co-therapy was found to be safe and suppressed CNS lesions in MS compared to GA 
alone [85].  Unfortunately, the majority of combination trials with GA did not contain a control 
group with immunomodulator alone; however, in comparing therapy outcomes to those seen with 
natalizumab it was found that the combination therapy did not improve efficacy [85].  A few 
studies have had success with a modified dosing schedule, where patients undergo short term use 
of immunosuppressant therapy, either with mitoxantrone or methylprednisolone, with GA before 
starting on GA alone [86, 87].  In addition to improving clinical outcomes compared to GA alone, 
it was also found that the short-term therapy limited the adverse effects associated with long-term 
immunosuppressive use [86].  
Although ASIT using only antigen has been successful in allergies, recent clinical trials with 
co-administration of an immunomodulator have been found to be more effective than allergen 
alone.  In several clinical studies omalizumab (Xolair), an anti-IgE antibody, was added to 
allergen hyposensitization therapy in the hope of decreasing the chance of dangerous side-
effects, such as anaphylaxis [88]. This combination therapy was found to increase efficacy as 
compared to the allergy-associated antigen alone [88, 89]. 
A slight variation of the use of ‘tolerogenic adjuvants’ in ASIT for autoimmunity is the 
success of traditional vaccine adjuvants co-administered with antigen for improved allergy 
hyposensitization therapy and ASIT for asthma [90].  When using traditional adjuvants for 
autoimmune therapy, the key to creating a successful ASIT for autoimmunity may reside in 




with a traditional vaccine adjuvant, alum, met with limited success [31].  Upon further trials, it 
was found that this treatment was successful in suppressing T1D but only in children and 
adolescents with recent onset of the disease [30].   In another successful clinical study, human B-
chain of insulin was given to patients with incomplete Freund’s adjuvant.  Although the focus of 
this study was safety, it was also found that patients had a robust antigen-specific Treg response 
even two years after finishing the treatment [91]. With the success of immunomodulator co-
administration in recent literature, it is possible that the addition of an immunosuppressant to 
traditional adjuvants combined with antigen may allow for even broader patient efficacy. 
 
6 Challenges for the Future of ASIT for Autoimmunity 
6.1 Human Translation of Pre-Clinical Successes 
Although there are promising results in animal models of autoimmune diseases, most 
successes in these models have not been translatable to humans.  One of the most promising 
methods for ASIT autoimmunity that had success in animal models was the administration of 
oral antigen to treat MS, T1D, or RA.  When attempted in humans, no therapeutic benefits were 
found [7, 8].  While it is difficult to interpret these negative findings, discrepancies in immune 
tolerance and autoimmunity between humans and animal models, such as mice, have been noted.  
These include differential expression of Treg markers such as FoxP3, variations in the balance of 
leukocyte subsets, dysregulation of central tolerance such as thymic selection, and different roles 
played by cells that produce IL-17, among others [92].  Directly linked to these immunological 
differences, the development of the disease in animals is often unrelated to that in humans.  
Often animal models of autoimmunity require induction with an immunogenic antigen, such as 




autoimmune disease can occur spontaneously such as NOD and some versions of EAE, which in 
some instances may offer better understanding of the human disease than inducible models [92, 
93].   
Acute animal models of autoimmunity also may not be predictive for the treatment of chronic 
human immune disorders.  The majority of animal studies conducted treat the disease before 
symptoms appear; whereas human therapies will mostly be given years after onset of the 
pathogenic process [8, 93].  Many animal studies are terminated too early to see any long term 
issues that may arise. For example, only 7% of all studies with NOD mice are followed up 
beyond 32 weeks, which does not reflect the lifelong duration of T1D in humans [92].  
Additionally, the complete disease causing mechanisms are not completely understood in 
humans.  For example, it has been hypothesized from studies of identical twins, that while there 
is a genetic component to many autoimmune disorders there is also additional “environmental” 
components that affect the disease that are not reflected in highly controlled pre-clinical studies 
and may lead to less than perfect applicability to human trials [94].   
Treatment safety and tolerability, which is immensely important in human therapies, is also 
often overlooked or difficult to assess in animal models [8].  Some safety issues may only arise 
in humans, and using cells from human donors in combination with animal models may help 
prevent toxic compounds from reaching the clinic [92].  For example, the production of a 
cytokine storm in humans using a CD28 agonist was not foreseen using animal models [92]. 
Nevertheless, these animal models have helped make important discoveries in the treatment 
of human autoimmunity. The EAE model of MS has helped identify four recently approved 
therapies; glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), 




immunology of human autoimmunity may increase the clinical success of experimental 
therapies. 
6.2 Antigen Identification and Epitope Spreading 
For many autoimmune diseases the animal model is not the rate-limiting step to developing 
ASIT; rather the immunodominant disease-causing antigen(s) may not be identified.  SLE, for 
example, can manifest symptoms in many different organs and the disease-causing autoantigen 
may vary greatly between SLE patients [95].  Even diseases that have relatively well-
characterized disease-causing antigens, such as MS, a single antigen for ASIT can be difficult to 
determine due to epitope spreading [96].  A few recent trials in MS have shown promise by using 
multiple antigens to elicit the antigen-specific response; however, they are still in the early stages 
of human testing [97, 98]. 
In allergy hyposensitization therapy, diagnostics, such as the skin prick test, determine the 
most important allergen in specific patients [99].  If this type of ‘personalized medicine’ could be 
applied to autoimmunity, it may greatly improve outcomes.  The analysis of peripheral blood for 
immunodominant autoantigens may allow for ASIT to be tailored to the individual patient, 
increasing the possibility for therapeutic success [92].  Emerging diagnostic practices such as 
component resolved testing, high-throughput antibody repertoire analysis, and indirect T-cell 
recognition assays may improve the ability to determine the correct autoantigen for personalized 
ASIT [100-102]. 
Autoimmune diseases with only one immunodominant antigen, including myasthenia gravis 
and neuromyelitis optica, may provide better targets for ASIT [103].  Recent studies using an 
antibody against the disease-causing antigen in neuromyelitis optica, aquaporin 4 have shown 




6.3 Immunomodulator Optimization 
While antigen(s) for ASIT are defined by the disease, there are a wide-array of 
immunomodulators to choose from when exploring combination therapy.  To date, the 
immunomodulator chosen for co-administration or co-delivery with antigen has been ad hoc at 
best. The majority of studies focus on a single immunomodulator in combination therapy for 
ASIT.  A few recent studies have attempted to determine the best tolerance-inducing 
immunomodulator by measuring the induction of Tregs by various small molecule 
immunosuppressants [105, 106].  However, a successful immunomodulator in one autoimmune 
disease may not be appropriate for another, and therefore immunomodulator screening may need 
to occur on a disease by disease basis.  Additionally, recent successes of combinations of 
immunomodulators for autoimmune treatment may indicate that multiple immunomodulators 
may be more effective for the induction of antigen-specific tolerance [107, 108]. 
Recent clinical successes have been achieved utilizing traditional adjuvants as 
immunomodulators in ASIT [30, 91].  Unfortunately, the viability of this method for the 
treatment of autoimmunity is still hotly debated as conflicting studies have shown that 
combinations of traditional adjuvants and antigen can both induce and treat autoimmune disease 
in rodent models. Immunologists have only recently started unraveling mechanisms such as 
immune cell ‘exhaustion’ in autoimmunity and immune tolerance pathways in cancer, both of 
which may have direct implications for ASIT combination therapy [109, 110]. 
6.4 Co-Delivery Vehicle  
Co-delivery adds an extra layer of complexity to the creation of ASIT for autoimmunity due 
to the need for the correct delivery vehicle, yet mounting evidence suggests co-delivery may do 




The determination of the correct co-delivery vehicle is important to ensure both antigen and 
immunomodulator interact with the immune response at the same time and in the same space.  
Numerous vehicles for co-delivery were utilized for combination therapy in ASIT reviewed here, 
including microparticles, nanoparticles, liposomes, direct chemical linkage, multivalent 
presentation on polymers, and plasmid DNA (Figure 2) [65, 71-75, 77-79].  Each of these 
approaches offers its own unique benefits, challenges, and potential. 
The particulate delivery systems; (e.g. microparticles, nanoparticles, and liposomes) most 
directly mimic the delivery systems currently employed in vaccines.  Vaccines commonly utilize 
aluminum salts, which are particulate in nature, to deliver the antigen of interest [111].  Recent 
studies with antigen conjugated to micro- and nanoparticles have successfully suppressed disease 
in EAE [112, 113].  These particulate systems are often intended to be immunologically inert; 
however, the material, size, and shape of the particles can promote immune responses [114, 115]. 
Particulate delivery systems are unique in that the antigen and immunomodulator may be on the 
surface of the particle, encapsulated, or both.  Particles with surface conjugated antigens may be 
preferred when targeting B-cells [115].  Surface antigens may also target T-cells when displayed 
in the context of MHC [116]. Alternatively, encapsulation of antigen is often used when uptake 
by APCs is preferred as much higher concentrations of antigen per particle can be achieved with 
encapsulation [115]. Encapsulation of antigen and/or immunomodulator can also improve 
pharmacokinetic properties; for example, encapsulation of antigen can decrease rapid dilution 
and clearance that is associated with many injected biologics [115].  
Multivalency may also influence the immune response, as it has been shown that the valency 
and the size of multivalent scaffolds play an important role in immunomodulation [114].  Dintzis 




immunogenicity or tolerogenic-properties of linear polymeric delivery systems [114, 117].  They 
found that polymers with a molecular weight greater than 100 kDa and a valency greater than 20 
compounds per polymer were more immunogenic, while systems under 100 kDa tended to be 
more tolerogenic [114].  Both particulate systems with surface-bound materials and linear 
polymers displaying antigens have utilized multivalency as an approach to ASIT combination 
therapy for autoimmunity [72, 77]. 
Plasmid DNA delivery systems have also been investigated for combination therapy, as both 
antigen and immunomodulator can be encoded onto a single plasmid [78, 79].  Antigen-specific 
treatments utilizing DNA have been shown to have benefits over whole protein or peptide 
antigens such as increased intercellular persistence due to stable expression from transduced 
genes [118].  Recent clinical trials utilizing a plasmid DNA encoding proinsulin demonstrated 
positive results in antigen-specific tolerance in T1D patients [119].   
Finally, a very unique delivery system of utilizing cells themselves as delivery vehicles for 
ASIT has emerged with the potential to induce antigen-specific tolerance in autoimmunity. In 
studies spanning several decades, Miller and colleagues have shown that chemically coupling 
antigen to apoptotic cells, can be used to induce antigen-specific tolerance [120, 121].  Antigens 
coupled to apoptotic splenocytes, peripheral blood leukocytes, or erythrocytes have had positive 
results in animal models of autoimmunity [121-123]. Additionally, these antigen-coupled cells 
have been tested in humans, and shown promising results in a Phase 1 clinical trial [124]. 
Another innovation utilizes cells treated with ASIT ex vivo.  In these systems, DCs are obtained 
from the bone marrow of genetically similar animals and treated with antigen and 
immunomodulator [80, 125].  The cells treated with the combination therapy are then injected 




utilizing a delivery system capable of removing the ‘middle-man’ of cellular uptake by APCs 
and co-delivery of immunomodulator, since cells are treated ex vivo.  Unfortunately, cell-based 
methods for ASIT are still relatively young and experimental.  Furthermore, the complexity of 
these systems may create difficulty in wide spread clinical application due to challenges 
associated with manufacturing, high cost, and patient accessibility [124].   
6.5 Route of Administration 
Recently published studies in animals have used a variety of different routes of 
administration including intravenous (IV), intramuscular (IM), and subcutaneous (SC), with 
over-arching success.  When translating these therapies to humans and larger animal models, the 
route of administration will certainly play an import role in clinical outcomes.  The route of 
administration dictates the barriers the therapy will face before reaching the site of action.  For 
example, oral therapies must migrate through the GI track and often undergo first-pass 
metabolism in the liver before entering circulation, whereas IV therapies bypass these barriers. 
The route of administration in animals may not be translatable to humans, such as the use of oral 
antigen administration for autoimmunity that was found to have minimal clinical efficacy [7, 8]. 
Many of the ASIT strategies utilize the interaction of immune cells in the lymphatic system 
in order to skew the immune response towards tolerance. It has been demonstrated that efficient 
delivery of vaccine components to the lymph nodes is critical to mounting an effective antigen-
specific response [126].  By optimizing delivery vehicle size, drainage to lymph nodes has been 
achieved from multiple different injection sites [127].  Nanoparticles ranging in size from 10 nm 
to 200 nm have been found to drain to the lymph nodes following injection [127].  SC delivery 
has been effective in both passive drainage and active transport by peripheral macrophages from 




transport as immune cells are often recruited to the depot at the injection site [114].  A unique 
route of administration, intranodal injection, bypasses the transport step.  Intranodal 
administration in allergy hyposensitization has been shown to safely promote antigen-specific 
tolerance while reducing dose size by up to 1000x the dose delivered via conventional routes 
[128]. 
 Allergy hyposensitization strategies have explored sublingual, intranasal, and oral routes of 
administration [1]. Sublingual treatment has yielded the greatest success as it increases 
convenience while maintaining the efficacy of the traditional SC therapy [4].  Recently, three 
sublingual hyposensitization therapies have been approved by the FDA to treat grass and 
ragweed allergies [129].  Historically, intranasal administration of hyposensitization therapy had 
suffered from a high number of local adverse events [130].  A new approach utilizing strips 
coated with dust-mite allergens reported positive outcomes in a recent clinical trial [131].  Oral 
hyposensitization to food allergens has also had some clinical success; however, there is still 
concern about serious adverse reactions, which could be addressed via combination therapy 
strategies proposed here [130]. 
 
7 Conclusion 
ASIT has long been the cornerstone of vaccines, arguably one of the most important 
healthcare related-inventions.  Mechanisms based on prototypical vaccine design have been 
effectively adapted for producing antigen-specific tolerance for allergies (i.e., hyposensitization 
therapy); however, the application towards clinical advancement of effective experimental ASIT 
therapeutics to treat autoimmune disease(s) has not been as successful.  As outlined above, the 




hold the key to developing successful ASIT for autoimmune disorders and potentially to improve 
current hyposensitization therapies.  Researchers have seen promising results in an array of 
experimental models of autoimmunity by both co-administration and/or co-delivery of 
autoantigen and immunomodulator as an enhanced ASIT treatment.  Future work should 
emphasize the effects of each component alone and together in combination therapies to enhance 
our understanding of the mechanisms by which tolerance is induced. As these strategies and 
experimental therapies evolve and move into the clinic, the outcomes of these studies may vastly 
change the way that autoimmune therapy is approached, especially with the potential to increase 
efficacy, diminish side effects, and reduce the lengthy dosing schedule of current 
hyposensitization therapy.  With several recent successful proof-of-principle studies, there is 
increased hope that ASIT combination therapy may hold the potential to cure the disease, rather 















Table 1. Mechanisms of action for ASIT to treat autoimmunity. 
Mechanism of Action Drug Example 
Cell Cycle Interference   
  Prevent Cell Division lefunomide 
  Inhibition of DNA Synthesis methotrexate 
Controlling Pro-Inflammatory Cytokines   
  Prevent Cytokine Production ciclosporin 
  Inhibit Receptor Binding tocilizumab 
  Induction of Neutralizing Antibodies  interferon-β 
Inhibiting Transport of Auto-reactive Cells   
  Preventing Cell-adhesion natalizumab 
  Trap Cells in Lymphatics finglomod 
Inhibiting T-cell Activation   
  Blocking B7 Co-stimulation abatacept 
  Blocking other Co-stimulation Pathways alemtuzumab 
  Competitive Inhibition of MHC Binding glatiramer acetate 
B-cell Depletion   
  Antibody-Dependent Cell Cytotoxicity rituximab 
Other Proposed Mechanism to Improve Therapies 
Auto-antibody Deletion 
Ex Vivo Antigen-specific Immune Cell Activation 
Anergy of Auto-reactive cells 
Inducing Regulatory Cell Proliferation 
Antigen-specific Interruption of T-cell Activation 







Figure 1. Current therapies for autoimmunity fall into distinct categories; including 
immunosuppressants, mobility inhibitors, co-stimulation and cell activation inhibitors, and 
antigen mimics.  These therapies act throughout the immune response, in the lymph tissue, in 
systemic circulation, and in the diseased tissue to suppress autoimmune disease symptoms. 
Therapies often act at several locations and the mechanism of action of many of them, 








Table 2. Definitions of Types of ASIT Delivery 
Term Definition Example 
Mono-therapy Single component therapy 




Multiple components given together in 
either the same time and/or same space 




Multiple components given together at 
the same time but not in the same space 
Injection of antigen and 
immunomodulatory drug together but not 
held together either chemically or 
physically 
Co-Delivery 
Multiple components given together in 
the same time and same space 
Antigen and immunomodulatory drug 
are linked, co-encapsulated, or held 


















Figure 2. Combination therapy for ASIT can be accomplished by either co-administration or co-
delivery of antigen and immunomodulator. With the increasing diversity of antigen and 
immunomodulatory molecules that could be used for ASIT, each independent combination 
therapy will have to be rationally designed to fit appropriate formulation parameters.  Several 
experimental technologies exist to temporally and/or spatially link antigen with 
immunomodulatory molecules.  These include 1) co-administration or formulation of 
independent components into a single injection solution and 2) co-delivery or physical linkage of 
the antigen and immunomodulatory molecule.  Both methods have shown positive ASIT data; 
















Dexamethasone OVA323-339 peptide Allergy [59] 
Dexamethasone Insulin-derived B:9-23 peptide T1D [59] 
FK-506 plasmid encoding MOG35-55 peptide MS [60] 
plasmid encoding IL-4 plasmid encoding PLP139-151 peptide MS [61] 
plasmid encoding IL-4 plasmid encoding MOG protein MS [61] 
plasmid encoding mutant B7-1 
(B7-1wa) 
fusion plasmid of PPIns-GAD65 proteins T1D [62] 
recombinant IL-10 MOG35-55 peptide MS [63] 




















Co-Delivery Vehicle Reference 
Dexamethasone MOG35-55 peptide MS 




MOG35-55, PLP139-151, and 
PLP18-191 peptides 
MS 
gold nanoparticles loaded on 






















or Bay 11-7082) 
OVA protein Allergy co-encapsulated in liposomes [73] 
Curcumin methylated BSA protein RA co-encapsulated in liposomes [73] 
LABL peptide 
(CD11a237-247) 
GAD65208-217 peptide T1D linked via spacer peptide   [74] 
LABL peptide 
(CD11a237-246) 
PLP139-151 peptide MS linked via spacer peptide  [75] 
LABL peptide 
(CD11a237-246) 
PLP139-151 peptide MS 
mulivalently linked to same 
hyaluronic acid polymer 
backbone 
[132] 
B7 pathway targeting 
peptide (B7AP, CD80-
CAP, or sF2) 
PLP139-151 peptide MS 
mulivalently linked to same 
hyaluronic acid polymer 
backbone 
[77] 
plasmid encoding IL-4 
plasmid encoding 
GAD65-IgG Fc fusion 
protein 
T1D encoded on same plasmid [78] 
plasmid encoding BAX 
plasmid encoding 
GAD65 






self-assembled nanoparticles of 
peptide and plasmid; used to treat 
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Chapter II: Co-Delivery of Autoantigen and B7 Pathway 






















Multiple sclerosis (MS) is a neurodegenerative disease characterized by an inflammatory 
reaction against proteins in the central nervous system (CNS) leading to nervous system 
dysfunction and paralysis [1-3].  Several FDA-approved therapies exist to treat patients with MS; 
however, these therapies do not cure the disease, but rather are designed to slow disease 
progression and manage symptoms [4-6].  Additionally, several of these therapies are associated 
with severe adverse events, compelling a need for safer and more efficacious therapies to treat 
patients with MS and other autoimmune disorders [4, 6, 7].  
Autoimmune diseases, such as MS, result from the breakdown of mechanisms controlling 
immune tolerance and the subsequent failure of the host immune system to distinguish self from 
non-self antigens [8, 9].  In MS, auto-reactive T-cells are thought to escape endogenous immune 
tolerance mechanisms, inflicting subsequent damage to the myelin sheath and leading to neural 
degeneration [1, 8, 10].  Classical immunology dictates that two signals are required for T-cell 
activation by professional antigen presenting cells (pAPCs); an antigen specific signal (signal 1) 
and a “context” or immunomodulatory signal (signal 2, co-stimulatory/inhibitory) that ultimately 
dictates the resulting immune response [8, 11, 12].  Co-delivery of both antigen and a co-
stimulatory context signal activates an antigen-specific adaptive immune response, whereas 
delivery of a co-inhibitory context signal or absence of either signal can render an anergic 
response (i.e. no response) and is believed to be a main mechanism of peripheral immune 
tolerance [8, 9, 13].  Thus, co-delivery of a synthetic co-inhibitory context signal and autoantigen 
may be a suitable pharmacological template to restore immune tolerance and treat various 




To mount appropriate immune responses, the immune system uses several cell surface 
signaling proteins such as those in the B7 (CD80/CD86) pathway, CD40, PD-1 (CD279), ICOS 
(CD278), and others [9, 11, 12].   The B7 signaling pathway is one of the most well 
characterized co-stimulatory pathways in T-cell activation [9, 11, 12].  B7, found on pAPCs, has 
the ability to either activate T-cells through binding with CD28 (co-stimulatory function) or to 
inhibit T-cell activation and promote tolerance upon binding CTLA-4 (co-inhibitory function) [9, 
11, 12].  The possibility to modulate the B7 signaling pathway has become an alluring avenue for 
the treatment of autoimmune disease, including MS.  Over the past decade, two recombinant 
fusion proteins targeting this co-stimulatory pathway through the use of portions of the CTLA-4 
molecule fused to IgG, Abatacept (Orencia, Bristol-Myers-Squibb) and Belatacept (Nulojix, 
Bristol-Myers-Squibb), have been approved for the treatment of rheumatoid arthritis (RA) and 
kidney transplant rejection, respectively [17].  
Unlike antibody derived therapeutics that can be immunogenic, small peptide therapies are 
less likely to be immunogenic and offer an alternative method of inhibiting activation of self-
reactive T-cells and pAPCs [14].  Methods employing peptides targeting different aspects of the 
B7 signaling pathway have been tested in animal models of RA, MS, and allograft rejection with 
positive results [18-21].  These peptide therapies are thought to work by blocking delivery of the 
co-stimulatory signal from the pAPC, resulting in T-cell anergy and promotion of tolerance to 
treat autoimmunity [14].  Therapies only targeting the B7 pathway share the same drawback as 
most current therapies for autoimmune disease as they are prone to non-specific suppression of 
the immune system rendering the patient more susceptible to opportunistic infections [13, 14].  
The creation of an antigen-specific treatment capable of suppressing the immune response by co-




autoimmune therapies.  Several previous studies have shown that co-delivering autoantigen and 
immune inhibitory peptide can inhibit autoimmune disease in animal models [22-28]. 
In this study, we tested whether co-delivering a B7-binding peptide and disease-specific 
autoantigen simultaneously would inhibit the autoimmune disease experimental autoimmune 
encephalomyelitis (EAE), a murine model of relapsing-remitting MS [29].  We grafted to 
hyaluronic acid both a myelin sheath antigenic peptide (PLP139-151) and peptides capable of 
binding B7 signaling pathway surface receptors by following previously reported procedures [15, 
24, 25].  The resulting soluble antigen arrays (SAgAs) act as a carrier to co-deliver multiple 
copies of the autoantigen and a peptide from the B7 pathway.  We investigated the clinical 
outcomes in EAE mice treated with these novel SAgA molecules and further characterized the 
cytokine expression in primary splenocytes isolated from SAgA-treated EAE mice. 
 
 
2. Materials and Methods 
 
2.1 Materials.  All peptides (PLP139-151, LABL, B7AP, CD80-CAP1, sF2 [cyclized]; Table 1) 
were obtained from PolyPeptide Laboratories (Torrance, CA) and were synthesized with N-
terminal aminooxy functional groups.  Hyaluronic acid (HA), with an average molecular 
weight of 16.0 kDa was purchased from Lifecore Biomedical (Chaska, MN).  Analytical 
grade acetonitrile and synthesis grade trifluoro acetic acid (TFA) were purchased from Fisher 
Scientific (Waltham, MA).  Research grade sodium acetate and acetic acid were purchased 
from Sigma (St. Louis, MO).  Complete Freund’s adjuvant (CFA) and killed Mycobacterium 
tuberculosis strain H37RA purchased from Difco (Sparks, MD). Water was provided by a 
Labconco (Kansas City, KS) Water PRO PS ultrapure water purification unit.   




peptides to 16 kDa hyaluronic acid (HA) was performed as described previously [24].  
Briefly, HA was dissolved in 20 mM acetate buffered solution (pH 5.5 ± 0.1) and each 
aminooxy reactive peptide was added simultaneously.  After addition of the peptides, the 
reaction solution was adjusted to pH 5.5 ± 0.1 and stirred at 500 RPM using a magnetic stir 
bar for 16 hr at room temperature.  The samples were then transferred to dialysis bags 
(MWCO 3500 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA) and dialyzed 
against 2 liters of deionized water for 24 hours, with dialysis water exchanged every 6 hours 
to remove unreacted peptides and residual buffer.  After dialysis, the dialysate was frozen at -
70 °C and lyophilized.   
2.3 Characterization of SAgAs by High Performance Liquid Chromatography. The amount 
of PLP and context signal- binding peptides conjugated to HA for each of the SAgAs was 
determined using digestion in acidic medium (4 hours at pH 2.0) and then subsequently 
analyzed by HPLC as previously reported [24].   For analysis of SAgAPLP:sF2, following 
peptide cleavage the solution was centrifuged for 5 min at 13,000 rpm and the aggregates 
were dissolved in DMSO before running both the pellet and supernatant on HPLC. The 
HPLC consisted of SCL-20A SHIMADZU system controller, LC-10AT VP SHIMADZU 
liquid chromatograph, SIL-10A XL SHIMADZU auto-injector set at 50 μL injection 
volumes, DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A SHIMADZU UV-
Vis detector (220 nm). The HPLC-UV system was controlled by a personal computer 
equipped with SHIMADZU class VP Software. All separations were carried out using a 
Vydac® 179 HPLC Protein and Peptide C18 column. Gradient elution was carried out to 
determine the amount of PLP and context signal peptide at constant flow of 1 mL/min, from 




elution at 75% B for 3 min.  Mobile phase compositions were (A) acetronitrile-water (5:95) 
with 0.1% TFA and (B) 100% acetonitrile with 0.1% trifluoroacetic acid (TFA).  
2.4 Characterization of SAgAs by Gel Permeation Chromatography.  The molecular weight 
of each SAgA was determined using a Shimadzu HPLC system with a refractive index 
detector previously described [15].  Samples were separated by utilizing a tandem column 
setup of an Agilent PL aquagel-OH 60 and Agilent PL aquagel-OH 40 column in series.  
Columns were heated to 45°C using an Eldex CH-150 heating box.  All pullulan standards 
and SAgAs were separated in a 0.1 M Ammonium Acetate, pH 5.0, with 0.25 M NaCl 
Mobile phase at a flow rate of 0.6mL/min for 45 min. 
2.5 Characterization of SAgAs by Micoflow Imaging (MFI). To detect particulates formed 
from SAgA aggregation microflow imaging (MFI) with a DPA-4200 flow microscope 
(Protein Simple, Santa Clara, CA) was used to capture digital images of subvisible particles 
with equivalent circular diameters from 1.5 to 100 µm.  Each SAgA and HA control were 
dissolved in 0.1mg/ml PBS and approximately 0.6 mL of each sample was analyzed.  Particle 
statistics were generated using MFI View Analysis Suite (MVAS) version 1.3 (Protein 
Simple, Santa Clara, CA). 
2.6 Induction of EAE and Therapeutic Study. SJL/J (H-2s) female mice, 4 – 6 weeks old, 
were purchased from Harlan Laboratory and housed under specified, pathogen-free 
conditions at The University of Kansas. All protocols involving live mice were approved by 
The University of Kansas Institutional Animal Care and Use Committee.  The PLP-induced 
model of EAE was used to mimic relapsing-remitting multiple sclerosis [29]. Mice were 
immunized subcutaneously with 200 mg of PLP139–151 in a 0.2 mL emulsion composed of 




containing killed Mycobacterium tuberculosis strain H37RA (final concentration of 4 
mg/mL; Difco). The PLP139–151/CFA was administered to regions above the shoulders and the 
flanks (total of four sites; 50 μL at each injection site). In addition, 200 ng of pertussis toxin 
(List Biological Laboratories Inc., Campbell, CA) was injected (100 μL) intraperitoneally on 
the day of immunization (day 0) and 2 days post-immunization. To inhibit disease, mice 
received subcutaneous injections (100 µL) at the nape of the neck of each SAgA sample or 
vehicle (sterile PBS), on days 4, 7, and 10.  SAgA dose was based on delivering 200nmol 
PLP peptide as calculated by HPLC.  Treatments of HA were administered at a dose 
equivalent of the SAgAs, 29 nMol.  Disease progression was evaluated blindly by the same 
observer using clinical scoring as follows: 0, no clinical signs of the disease; 1, tail weakness 
or limp tail; 2, paraparesis (weakness or incomplete paralysis of one or two hind limbs); 3, 
paraplegia (complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness or 
paralysis; and 5, moribund.  Mice were euthanized if they were found to have a clinical score 
of 4 or above. Body weight was also measured daily and is expressed as a percent weight loss 
calculated from day 8 (peak weight prior to EAE-disease). The total duration of the EAE 
study was 26 days, from day 0 to day 25. 
2.7 Splenocyte Isolation and ex vivo treatment of splenocytes.  Mouse spleens were resected 
25 days post immunization, passed through a wire mesh using the rubber end of a sterile 1 
mL syringe plunger, and collected in 5 mL of RPMI 1640 media.  The crude cellular extract 
was then centrifuged at 1,100 x g for 5 minutes and the resulting cell pellet was resuspended 
in 3.5 ml of 1x Gey’s lysis solution and place on ice for 3.5 minutes to lyse splenic red blood 
cells.  The lysis reaction was stopped by the addition of 10.5 ml RPMI 1640 media 




was resuspended in fresh media (RPMI 1640 media containing 10% FBS and 1% Penicillin-
Streptomycin) and seeded in 96-well cell culture plates at a cell density of 1x10^6 cells/well 
in a final volume of 100 µl.  Splenocytes were then immediately stimulated with 25 µM PLP 
or vehicle (RPMI media).  Stimulated cell cultures were incubated for 120 hours at 37°C in a 
CO2 (5%) incubator.  Cell culture supernatant levels of cytokines were determined by a 
commercially available bead array ELISA kit and supporting FlowCytomix ™ software 
(ebiosciences, San Diego, CA).  
2.8 Statistical analysis. Statistical evaluation of data was performed using a one-way or two-
way analysis of variance (ANOVA) as experimentally appropriate, followed by Fisher’s least 
significant difference post-hoc test. The criteria for statistical significance was set at p<0.05. 
All analyses were performed using GraphPad Software (GraphPad Software Inc.). 
 
3. Results 
3.1. Synthesis and Characterization of Soluble Antigen Arrays 
Peptides selected for use in this study were previously shown to interact with and modulate 
the B7 signaling pathway (Table 1) [18-20, 30, 31].  SAgAs targeting the B7 pathway were 
created by co-grafting to hyaluronic acid polymers (HA) both autoantigen (PLP139-151) and B7-
binding peptides (B7AP, CD80-CAP, or sF2) as previously reported [15, 24, 25].  For a positive 
control, an ICAM-1-targeted SAgA (SAgAPLP:LABL) was created containing autoantigen (PLP139-
151)  and the cell adhesion peptide LABL derived from leukocyte function associated antigen-1 
(LFA-1), which has previously shown efficacy in EAE [24, 25]   
High performance liquid chromatography (HPLC) was used to determine the amount of 




molecule was determined (Table 2).  Further analysis by gel permeation chromatography (GPC) 
was used to confirm the final molecular weight of the SAgAs upon peptide conjugation (Table 
3).  Final conjugate molecular weights of approximately 37 to 47 kDa estimated using these two 
methods were overall in agreement; however, the molecular weight of SAgAPLP:sF2 found by 
GPC was approximately double that originally estimated by HPLC suggesting possible 
aggregation. 
Micro-flow imaging (MFI) analysis of SAgAPLP:sF2 revealed the presence of particles, 
confirming formation of SAgAPLP:sF2 aggregates in aqueous solutions (Figure 1).  Upon 
observation of the aggregation and poor solubility, SAgAPLP:sF2  was solubilized in DMSO 
following peptide cleavage from the HA backbone.  Subsequent analysis of SAgAPLP:sF2 by 
HPLC confirmed a similar conjugation efficiency compared to the other SAgAs, with 
approximately 7 to 11 peptides per HA backbone of both autoantigen and B7-binding peptide 
(Tables 2 and 3).  
3.2. Suppression of EAE by Soluble Antigen Arrays 
Soluble Antigen Arrays (SAgAs) co-grafted with autoantigen (PLP) and B7-binding peptide 
were evaluated in EAE to determine their effect on disease progression.  Similar to previous 
studies, the positive control SAgAPLP:LABL suppressed EAE as indicated by clinical score and 
weight loss (Figure 2) [24, 25].  Additionally, HA alone did not effect EAE disease scores as 
compared to the negative control, PBS.  Interestingly, compared to PBS all B7-targeted SAgAs 
were able suppress the symptoms of EAE as evaluated by clinical disease score and weight loss 
(Figure 2).  All SAgAs also reduced the incidence of disease compared to mice treated with PBS 




disease were found between the SAgAs containing different context signal peptides.  The data 
suggests that co-delivery of B7-binding peptides and autoantigen can protect against EAE. 
3.3. SAgAs containing B7AP peptide reduced pro-inflammatory cytokine production 
To analyze the ability of immune cells in the periphery to respond to re-challenge with PLP, 
the cytokines GM-CSF, IFN-γ, TNF-α, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-17 were 
measured from splenocytes taken from animals treated with B7-targeted SAgAs or controls 
(Figure 4).  Splenocytes were harvested on Day 25 and were cultured directly in the presence of 
PLP (25 µM) to re-stimulate the immune cells.  GM-CSF and IL-2, but not IFN-γ, TNF-α, IL-1α, 
IL-4, IL-5, IL-6, IL-10, or IL-17, increased in PLP-stimulated splenocytes isolated from PBS-
treated EAE mice (Figure 4).  Levels of IL-10 were below the limit of detection for all treatment 
groups using this assay (data not shown).  Interestingly, the PLP-dependent induction of the pro-
inflammatory cytokines IL-2 and GM-CSF was reduced in EAE splenocytes from mice treated 
with SAgAPLP:B7AP as compared to mice given PBS.  Decreased levels of GM-CSF were also 
found in PLP-stimulated EAE splenocytes from mice treated with SAgAPLP:sF2  or with HA as 
compared to the mice treated with PBS.  In EAE mice treated with SAgAPLP:sF2,  basal levels of 
IL-6 were not detectable.  The data suggested each independent SAgA differentially modulated 
the cytokine response in splenocytes isolated from EAE mice. 
 
4. Discussion  
The B7 signaling pathway has emerged as an important target for immune modulation, with 
several experimental biologic therapeutics entering clinical trials [17].  For autoimmune diseases, 
the ability to suppress unwanted immunity by blocking co-stimulation during antigen 




dependent tissue damage [13, 17].  Addition of antigen specificity to such an approach may 
reduce undesired side effects associated with global immunosuppression that accompanies many 
of the current immunomodulatory therapies available [4-7].  Indeed, several groups have begun 
investigating antigen specific immunotherapies to treat autoimmune disorders [22-28, 32-36]. 
Previously, a bifunctional peptide inhibitor (BPI) demonstrated the importance of co-
delivering both antigenic peptide and a peptide inhibiting T-cell activation by blocking immune 
cell adhesion [22, 23, 26-28].  Applying this co-delivery approach of autoantigen and peptide 
inhibitor to a multivalent delivery vehicle (SAgAPLP:LABL), i.e. multiple copies of peptide per 
therapeutic molecule, has also suppressed EAE [24, 25].  In this study, multivalent SAgA 
technology was used as a foundation to synthesize new SAgAs (SAgAPLP:B7AP, SAgAPLP:CD80-CAP, 
SAgAPLP:sF2) that target the B7 signaling pathway and co-deliver PLP autoantigen for the 
treatment of EAE. 
The B7 pathway can deliver either a co-stimulatory or co-inhibitory signal during antigen 
presentation depending on the combinations of surface receptors engaged [12].  In order to 
investigate the application of SAgAs targeting the B7 pathway we selected three peptides 
(B7AP, CD80-CAP, sF2), which had been previously reported to bind B7 (Table 1).  Two 
peptides used in this study, B7AP and CD80-CAP, have been shown to inhibit inflammatory 
immune response in several rodent autoimmune models [18-20, 30, 37].  In contrast, the peptide 
mimic of CTLA-4 (sF2) was originally selected for this study as a positive control to enhance the 
immune response by blocking the B7:CTLA-4 regulatory interactions [31].  The reported 
mechanisms of these peptides led us to hypothesize that SAgAPLP:B7AP and SAgAPLP:CD80-CAP 
would suppress EAE disease severity, while SAgAPLP:sF2 would increase disease severity in EAE. 




however, help explain this result.  CTLA-4-IgG and soluble CTLA-4 have been shown to have 
inhibitory functions in several in vivo models, suggesting that delivery of a multivalent CTLA-4 
mimetic peptide (i.e. SAgAPLP:sF2) may actually suppress pro-inflammatory immune responses 
[38, 39].  Additionally, current immunological models suggest that “over-stimulation” of T-cells 
may induce anergy and be a mechanism of both peripheral and central tolerance [40].  Delivering 
multivalent SAgAs that achieve simultaneous high local concentrations of antigen and context 
signal (i.e. multiple copies of each peptide per molecule) may overwhelm sensitive immune cells 
and subsequently induce anergy. 
In addition, all B7-targeted SAgAs were shown to have similar clinical efficacy as 
SAgAPLP:LABL, which has be shown to inhibit the symptoms EAE in previous studies [24, 25]. 
Although the SAgAs may be equivalent in the suppression of EAE symptoms, the B7-targeted 
SAgAs offer an advantage over their ICAM-1-targeted counterparts. Unlike the molecular 
signals of the B7 pathway, which are only found on either pAPCs or T-cells, ICAM-1 is found 
on immune cells, endothelial cells, and even in soluble form in the blood [8]. Additionally, 
previous studies have demonstrated that the conjugation of only PLP to HA does not result in 
EAE suppression [25].   The importance of the context signal peptide for the suppression of EAE 
suggests that optimization this peptide may enhance SAgA efficacy.  While SAgAPLP:LABL  has 
not demonstrated any off-target effects in previous studies, the specificity of the B7-targeting 
SAgAs may result in more effective delivery of the SAgA to their immune cell targets. 
Although all SAgAs reduced clinical disease similarly, several differences between each of 
the unique SAgA molecules were noted in splenocytes that were re-challenged with PLP.  
Interestingly, only splenocytes isolated from mice treated with SAgAPLP:B7AP had reduced levels 




contribute to increased disease severity in EAE [1, 41].  Additionally, SAgAPLP:B7AP, SAgAPLP:sF2, 
and HA treatments inhibited PLP-dependent GM-CSF cytokine expression, a cytokine suggested 
to play a role in EAE disease progression [8, 42].  HA alone did not suppress disease symptoms 
compared to PBS, indicating that reduction of GM-CSF cytokine levels may not be an accurate 
indicator of in vivo efficacy.  
Furthermore, SAgAPLP:sF2 was the only SAgA shown to form aggregates in a physiological 
buffer.  Particulate adjuvants used in traditional prophylactic vaccines elicit their immune effect 
in part through recruitment of pAPCs to the site of injection and by stimulating a local pro-
inflammatory immune response at the site of antigen recognition [43, 44].  In contrast, clinical 
treatment of allergies induces tolerogenic immune responses through a series of injections of 
soluble antigens in the absence of adjuvant (i.e. particles), which can bypass the local pro-
inflammatory response [16].  Indeed, SAgAPLP:sF2  aggregates may form a depot at the site of 
injection, which may cause local inflammation and recruitment of cells.  The suppression of EAE 
by SAgAPLP:sF2 may suggest that formulation of non-soluble (colloidal) treatments for co-
delivery of antigen and context signal may also be a viable strategy for development of 
tolerogenic autoimmune therapies.  When taken together, the cytokine and particulate data 
suggest that the different B7-targeted SAgAs protect against EAE disease progression by slightly 
different immunological mechanisms.  
 
5. Conclusion 
The B7 signaling pathway is a promising target for the treatment of EAE using SAgA 
technology.  Both B7-targeted and ICAM-1-targeted SAgAs were found to suppress clinical 




indicates that although all SAgAs resulted in similar in vivo clinical efficacy, they may act 
through different immunological mechanisms at the cellular level.  These results suggest that 
targeting other surface receptors on immune cells may be a beneficial therapeutic option for the 
treatment of autoimmune disorders.  Furthermore, SAgA technology provides an easily 
adaptable platform to test a diverse library of multivalent peptide therapies targeting immune cell 
surface receptors and antigenic epitopes.  Expansion and customization of SAgA-based 





























a Each peptide was created to mimic a signaling molecule in the B7 pathway and has been previously 
shown to block B7 pathway signaling interactions.  




















Table 2. SAgA Peptide Conjugation 
          















205 277 9:11 
SAgAPLP:B7AP 
 
170 223 7:09 
SAgAPLP:CD80-
CAP 
233 220 9:08 
SAgAPLP:sF2* 
 
212 152 10:7* 
a Each SAgA molecule was analyzed by HPLC following acidic cleavage of peptides from the 16kDa HA 
backbone.  The peptide concentrations were calculated based on HPLC analysis of 1 mg of SAgA.  
Results shown are an average from triplicate injections of a single batch preparation.  All samples had a 
RSD≤ 0.01. 














    
      
  
      
    
  
  
    
    
  
      
      
  
      
  
    
    
  




Table 3. SAgA Molecular Weight Calculation by both HPLC and GPC 
Soluble Antigen 
Array 






from GPC data 
(kDa)a 
SAgAPLP:LABL 42 44 
SAgAPLP:B7AP 42 41 
SAgAPLP:CD80-CAP 37 42 
SAgAPLP:sF2* 47* 45 
a The molecular weight of each SAgA was calculated from GPC data as compared to a pullulan polymer 
standard curve. Results shown are an average from triplicate injections of a single batch preparation.  All 
samples had a RSD≤ 0.01. 




















Figure 1. ICAM-1 and B7-targeted SAgAs were analyzed for subvisible particulate formation at 
a concentration of 0.1 mg/ml in PBS using mico-flow imaging (MFI).  A) Concentrations of 
particles of equivalent circular diameters from 1.5 μm to 10.5 μm are shown for SAgAPLP:sF2, 
SAgAPLP:LABL, SAgAPLP:B7AP, SAgAPLP:CD80-CAP, and HA alone.  B) Representative images of 
insoluble aggregates from 25 to 70 µm equivalent circular diameter are shown. (Data presented 





Figure 2. ICAM-1 and B7-targeted SAgAs were found to decrease both clinical score and 
maintain weight in EAE mice.  EAE was induced on day zero, and mice were treated on days 
four, seven, and ten with a dose of SAgA equivalent to 200 nMol PLP.  Treatments of HA were 
administered at a dose equivalent of the SAgAs, 29 nMol.  Clinical disease score and percent 
weight change were analyzed for groups treated with (A-B) SAgAPLP:B7AP, (C-D) SAgAPLP:CD80-
CAP, and (E-F)  SAgAPLP:sF2 .  All SAgAs significantly suppressed clinical disease score as 
compared to PBS on Days 11 to 15 and as compared to HA on Days 11 to 14.  Also, all SAgAs 
suppressed weight loss as compared to PBS on Days 11 to 18 and as compared to HA on Days 
12 to 16.  There were no statistical differences in disease suppression as indicated by both 
clinical score and weight loss between SAgAs containing different B7-binding peptides.  
Additionally, there were no statistical differences between PBS and HA control groups.  (Data 





Figure 3. ICAM-1 and B7-targeted SAgAs were found to reduce disease incidence in EAE mice.  
EAE was induced on day zero, and mice were treated on days four, seven, and ten with a dose of 
SAgA equivaent to 200 nMol PLP. Treatments of HA were administered at a dose equivalent of 
the SAgAs, 29 nMol.  EAE disease incidence was evaluated such that disease free animals 
maintained a clinical score <1.  In all the SAgA treatment groups, over half of the animals 
remained disease free over the course of the study, while in both negative control groups all 














Figure 4. The cytokines GM-CSF, IFN-γ, TNF-α, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-17 
were measured from splenocytes taken on Day 25 from animals treated with B7-targeted SAgAs 
or controls. The splenocytes were re-stimulated with 25 µM PLP or vehicle (media) in vitro for 
120 hours. Supernatant levels of the cytokines (A) GM-CSF, (B) IFN-γ, (C) TNF-α, (D) IL-1α, 
(E) IL-2, (F) IL-4, (G) IL-6, (H) IL-6, and (I) IL-17 were determined.  Cytokine expression of 
IL-2 and GM-CSF was significantly reduced in splenocytes isolates from EAE mice treated with 
B7-targeted SAgAs.   (Data are presented as mean ± S.D. of independent splenocyte populations 
isolated from 3 mice, gray bars indicate stimulated with 25 µM PLP, black bars indicate vehicle 
or media control, * indicates p<0.05 as compared to PBS-treated in vivo and stimulated in vitro 
with 25 µM PLP, and  # indicates p<0.05 as compared to the same in vivo treatment with 25 µM 
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Chapter III: Screening immunomodulators to skew the 
























Autoimmune diseases occur due to the breakdown of immune tolerance towards 
autoantigens, resulting in the inability of the immune response to distinguish self from non-self.  
Current treatments for autoimmune diseases are often unsuccessful in stopping or reversing 
disease progression, and often utilize broadly active immunosuppressants.  For example, the 
immunosuppressant FK-506 (Tacrolimus) has been used for the treatment of several autoimmune 
diseases including psoriasis, systemic lupus erythematosus, rheumatoid arthritis, and multiple 
sclerosis (MS); all of which have very different immune pathologies [1-6].  While 
immunosuppressants have been effective in many patients and are currently the ‘gold standard’ 
therapy, their benefits are often counterbalanced by toxicities or adverse side-effects [7, 8].  
Antigen-specific immunotherapy has long been the ‘holy grail’ of autoimmune treatments. 
The ability to suppress the immune response against autoantigens without non-specific global 
immunosuppression would allow for disease treatment without hindering the ability of the 
patient’s immune system to fight off foreign or opportunistic pathogens.  Although different in 
desired immunological outcome, vaccines are the quintessential example of the potential impact 
of guiding antigen-specific immune responses [9, 10].   In order to elicit an immune response to 
a specific antigen, vaccines must often be combined with a secondary signal, or adjuvant, to 
direct and enhance the antigen-specific immune response [10].  An adjuvant may be defined as a 
substance capable of enhancing the potency, quality, or longevity of an antigen-specific immune 
response [11].  While traditional adjuvants have been used to induce protective immune 
responses against foreign pathogens, it may be possible to skew the response in the opposite 
direction, towards antigen-specific tolerance by what may be referred to as a ‘tolerogenic 




Unlike vaccines, antigen-specific immunotherapies (ASIT) applied to allergies or 
autoimmune diseases have typically utilized the disease-causing antigen without an adjuvant. 
The use of ASIT to induce tolerance to a particular antigen has been around for over a century in 
the form of allergen hyposensitization therapy, in which small doses of allergen are administered 
over an extended period of time to induce immune tolerance [13].  Similar methods have been 
investigated for autoimmunity where the disease-causing autoantigen is administered in an effort 
to create autoantigen-specific tolerance.  Unfortunately, the success of autoantigen-only ASIT 
applied to autoimmunity has been modest [9, 14-16].  Attempts to create ASIT have also utilized 
traditional adjuvants to boost the immune response; however, the efficacy of this strategy has 
been limited [17, 18].  Recent studies have suggested that combining autoantigen with an 
immunosuppressant may substantially improve ASIT for autoimmunity by creating a tolerogenic 
antigen-specific immune response [12, 19-24].  
Over the last decade a novel tolerance-induction therapy has emerged in which 
immunosuppressants (hence forth referred to as immunomodulators) are used in a similar 
mechanism as traditional adjuvants to enhance immune tolerance to disease-causing autoantigens 
in autoimmunity.  Recent studies indicate that antigen-specific immune tolerance may be 
achieved by administration of a combination of a disease-causing autoantigen and an 
immunomodulator [12, 19-24].  Immunomodulators used in this context have been referred to as 
‘tolerogenic adjuvants’ in order to describe their ability to direct the immune response to an 
antigen [19, 25-27].  The majority of these studies have been conducted ad hoc, often on only 
one compound at a time.  We observed the need for a screening method to compare these 





Current drug screening in the pharmaceutical industry often utilizes systems containing a 
single target molecule or cell type in order to perform high-throughput analysis [28].  The use of 
these simple systems can allow for predictions of specific drug target interactions, but has largely 
been unsuccessful at predicting the result on complex cellular interactions, such as the immune 
response [29].  The diversity of factors effecting the immune response in treatment of diseases 
such as autoimmunity may benefit from a more complex screening system.  Recent progress has 
been made in the area of ‘physiological screening’, where full tissues are used to better 
understand drug effects of diverse cellular systems [30].  Techniques including whole organ 
culture, organotypic culture (use of heterogeneous cell cultures to mimic in vivo environments), 
three-dimensional culture, and primary cell cultures have been investigated in order to better 
mimic the complexity of an in vivo system in an in vitro environment for improved drug 
screening [29]. 
Primary splenocytes in particular are a promising system with which to perform drug 
screening. As the largest secondary lymphoid organ, the spleen contains a complex immune cell 
population that migrates to and from the organ as cells travel throughout the body [31].  In the 
context of the treatment of autoimmune diseases, the spleen is also important as it assists in 
peripheral tolerance to autoantigens [31].  Splenic antigen presenting cells promote peripheral 
tolerance through uptake and identification of apoptotic debris as non-immunogenic [31].  The 
spleen has also been shown to be the primary site for interaction between regulatory T-cells and 
auto-reactive T-cells in the treatment of a murine model of the autoimmune disease multiple 
sclerosis (MS), known as experimental autoimmune encephalomyelitis (EAE) [32].  
The use of a primary cell system such as splenocytes offers many benefits over immortalized 




response.  EAE has been used in the discovery of several FDA approved drugs for MS, including 
glatiramir acetate (Copaxone), miroxantrone (Novantrone), natalizumab (Tysabri), and 
fingolimod (Gilenya) [33].  The version of EAE examined in the following study utilized an 
epitope from a myelin sheath protein, proteolipid protein (PLP), known to be one of the many 
disease-causing autoantigens in human MS [34].  EAE induced by PLP139-151 mimics the 
relapsing-remitting form of MS, which affects approximately 80% of MS patients [35, 36].  
Although in both MS and EAE the majority of disease progression occurs in the CNS, 
throughout the course of the disease antigen-specific immune cells return to lymphoid organs to 
expand the immune response such that antigen-specific cells can be found in the spleen [37, 38].  
The use of antigen-educated EAE splenocytes offers a complex antigen-specific environment to 
facilitate drug screening while minimizing animal use.  
Many investigations performed on splenocytes obtained from EAE mice have indicated the 
potential to discern the antigen-specific immune response ex vivo.  Rechallenge with PLP ex vivo 
has facilitated examination of immune response following in vivo treatment [38, 39].  Studies 
utilizing ex vivo rechallenge with antigen have also improved understanding of epitope spreading 
in EAE [40, 41].  Although EAE splenocytes have been widely used as an antigen-specific ex 
vivo system, there is no record of their use as a screening system for potential therapeutics. 
Alternatively, a few other studies have reported in vitro screening of immunomodulators to 
induce tolerance; however, these studies have not used cells obtained from an autoimmune 
model system [42, 43].  Here, we utilized antigen-specific splenocytes obtained from EAE mice 
to screen immunomodulators for their ability to skew the antigen-specific immune response in an 




immunomodulator therapies (Table 2) were added during autoantigen rechallenge to determine 
if splenocyte response could be skewed towards markers of immune tolerance.    
 
 
2. Materials and Methods 
 
2.1 Materials.  The peptide antigen, PLP139-151(HSLGKWLGHPDKF) was obtained from 
PolyPeptide Laboratories (Torrance, CA).  For EAE induction incomplete Freund’s adjuvant 
(IFA) and killed Mycobacterium tuberculosis strain H37RA were purchased from Difco 
(Sparks, MD), and pertussis toxin was purchased from List Biological Laboratories 
(Campbell, CA).  Several immunomodulators were purchased from Sigma-Aldrich (St. 
Louis, MO), including dexamethasone, simvastatin, andrographolide, dimethyl fumarate, 
monomethyl fumarate, and lipopolysaccharide (LPS) from E. coli. Rapamycin, FK-506, and 
ibrutinib were obtained from LC Laboratories (Woburn, MA). Pure curcumin was obtained 
from Nacalai Tesque Inc. (Kyoto, Japan). Imiquimod (4-amino-1-isobutyl-1H-imidazo[4,5-
c]quinoline) was purchased from Accela ChemBio Inc (San Diego, CA). Pam2CSK4 was 
purchased from Tocris Bioscience (Avonmouth, Bristol, United Kingdom). Mammalian 
TGF-β1(from HEK293 Cells) was obtained from PeproTech (Rocky Hill, NJ). For imaging 
and flow cytometry studies, Alexa Fluor 488- conjugated anti-mouse CD3, Alexa Fluor 647-
conjugated anti-mouse CD22, and R-phycoerythrin-conjugated anti-mouse CD4 antibodies 
and their respective isotype controls were purchased from Biolegend (San Diego, CA). All 
other chemicals and reagents were analytical grade and used as received. 
2.2 Induction of EAE.  SJL/J female mice, 4 – 5 weeks old, were purchased from Envigo 




University of Kansas. All protocols involving live mice were approved by The University of 
Kansas Institutional Animal Care and Use Committee.  Mice were immunized 
subcutaneously with 200 µg of PLP139–151 in a 0.2 mL emulsion composed of equal volumes 
of phosphate-buffered saline (PBS) and incomplete Freund’s adjuvant (IFA) containing 
killed Mycobacterium tuberculosis strain H37RA at a final concentration of 4 mg/mL. The 
PLP139–151/CFA was administered to regions above the shoulders and the flanks (total of four 
sites; 50 μL at each injection site). In addition, 100 µL of pertussis toxin (200 ng) was 
injected intraperitoneally on the day of immunization (day 0) and 2 days post-immunization. 
Disease progression was evaluated using clinical scoring as follows: 0, no clinical signs of 
the disease; 1, tail weakness or limp tail; 2, paraparesis (weakness or incomplete paralysis of 
one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia 
with forelimb weakness or paralysis; and 5, moribund.  Body weight was also measured 
daily.  
2.3 Splenocyte isolation and ex vivo treatment. Mouse spleens were resected from EAE mice 
at peak of disease (11-13 days post immunization) and cultured as previously described [44].  
Briefly, the spleens were first passed through a wire mesh using the rubber end of a sterile 1 
mL syringe plunger, and collected in 5 mL of RPMI 1640 media.  The crude cellular extract 
was then centrifuged and the resulting cell pellet was resuspended in 3.5 ml of 1x Gey’s lysis 
solution and placed on ice for 3.5 minutes to lyse splenic red blood cells.  The lysis reaction 
was stopped by the addition of 10 ml RPMI 1640 media containing 10% FBS and 
centrifuged at 1,100 x g for 5 minutes.  The remaining cell pellet was resuspended in fresh 
media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and seeded 




1 only) in a final volume of 1 ml.  Splenocytes were plated as biological replicates, with 
spleens of similar disease severity pooled together as needed.  The cells were immediately 
treated with the immunomodulatory compound of interest, both with and without 25 µM 
PLP.  Stimulated cell cultures were incubated for 120 hours at 37°C in a CO2 (5%) 
incubator.  
2.4 Measurement of cytokines and cellular metabolism. Supernatants of cell cultures were 
collected after 120 hour incubation post spleen harvest. Secreted TNF-α, IL-2, IFN-γ, and IL-
10 were detected by individual ELISA assay kits (R&D Systems). Cell metabolism was 
determined by a resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) assay. Briefly, 
resazurin (75 µmol/L final) was added to splenocyte cultures and incubated for 3 hours. 
Metabolic reductive capacity was determined by a change in fluorescence (excitation 
560/emission 590). Background fluorescence was determined in RPMI media and was 
subtracted from each experimental read. All fluorescent readings were performed using a 
Spectramax M5 (Molecular Devices) plate reader. 
2.5 Fluorescent staining. For imaging and flow cytometry experiments, immediately after 
isolation splenocytes were seeded in 12-well cell culture plates at a cell density of 7.5x106 
cells/well in a final volume of 1.5mL. Treatments were then given at the concentration of 
interest, both with and without 25 µM PLP.  Stimulated cell cultures were incubated for 120 
hours at 37°C in a CO2 (5%) incubator. At 120hrs, cells were fixed using 4% 
paraformaldehyde fixation buffer for 15 minutes on ice.  Following fixation, splenocytes 
were stained with the desired antibodies. Briefly, 1x106 cells were washed with 1mL of wash 
buffer (RPMI 1640 media containing 5% FBS) before centrifugation and resuspension in 50 




Biolegend) in wash buffer.  Cells were incubated on ice for 25 minutes before adding the 
desired antibodies or isotype controls in 50 µL at 2x the manufacturer recommended 
concentration for 1 hour.  Finally, cells were washed three times and the nuclei were stained 
with Hoechst 3342 (Life Technologies, Eugene, OR). 
2.6 Imaging and flow cytometry. Cell imaging was conducted in a 96-well glass bottom plate 
(In Vitro Scientific, Sunnyvale, CA) using an Olympus IX81 inverted epiflourescent 
microscope using 60x magnification.  Variations in light intensity were corrected using 
corresponding isotype controls in Slidebook 6 Software.  For flow cytometry analysis 50,000 
cells per sample were detected using a BD FACSFusion cytometer. Data was analyzed using 
FlowJo Software. 
2.7 Statistical analysis. Statistical evaluation of data was performed using a two-way analysis of 
variance (ANOVA), followed by Tukey and Sidak multiple comparison tests. For figures 
composed of multiple splenocyte isolation experiments, data is presented as fold change from 
vehicle and was normalized to the vehicle controls (0.1% DMSO) with no antigen for each 
splenocyte isolation experiment. IC50 values were determined using a 4PL-sigmodal 
function. A single outlier data point was removed from rapamycin and dexamethasone 
concentration curves (Figure 4) following analysis via the Grubbs’ Outlier Test. The criteria 
for statistical significance was set at p<0.05. All analyses were performed using GraphPad 






3.1. Characterization of an Antigen-Educated System Capable of Demonstrating 
Immune Response 
In order to create a robust screening methodology, the model disease system of EAE 
splenocytes was thoroughly tested.  First, the antigen-specific immune response to proteolipid 
peptide (PLP139-151) was analyzed by comparing splenocytes obtained from both healthy mice 
and mice that had developed EAE symptoms (day 11-13 post-disease induction).  To observe 
antigen-specific immune responses, healthy and EAE splenocytes were rechallenged with 25 μM 
PLP and analyzed for cellular metabolic activity and cytokine response.  Cellular metabolic 
activity was found to significantly increase in EAE splenocytes as compared to healthy 
splenocytes, both with and without rechallenge (Figure 1A). Splenocytes obtained from healthy 
mice did not demonstrate any significant differences with and without rechallenge with antigen 
(Figure 1).  Additionally, healthy splenocytes rechallenged with PLP produced a significantly 
lower cytokine response in all cytokines measured as compared to EAE rechallenged with PLP 
(Figure 1B-E).  For all cytokines measured, EAE splenocytes had significantly higher levels 
when rechallenged with 25 µM PLP compared to no rechallenge (Figure 1B-E).  The length of 
PLP rechallenge was also determined in EAE splenocytes to identify a time point that offered the 
most discernable differences for cellular metabolic activity and cytokine responses (Figure 2). 
Several controls were analyzed in EAE splenocytes to establish the robustness of the 
screening system, including three immunogenic controls, imiquimod, Pam2CSK4, and 
lipopolysaccharide (LPS), and a tolerogenic control, TGF-β (Table 1).  Our vehicle control, 
0.1% DMSO, was also compared to the effect of media alone to confirm that the vehicle did not 
influence the immune response.  All cell metabolic activity and cytokine results were normalized 




Cell metabolic activity with 25 μM PLP was shown to significantly increase upon imiquimod 
treatment with PLP rechallenge, Pam2CSK4 treatment without rechallenge, and significantly 
decrease with TGF-β treatment both with and without rechallenge as compared to the vehicle 
(Figure 3A).  Pam2CSK4 was also found to increase IFN-γ upon rechallenge with antigen as 
compared to vehicle (Figure 3C).  Multiple cytokines were found to significantly increase upon 
LPS treatment as compared to vehicle, both with PLP rechallenge (TNF-α, IFN-γ, IL-10) and 
without rechallenge (TNF-α, IL-2, IL-10) (Figure 3B-E).  Overall these results align with 
previously reported immune effects of the control compounds, verifying the ability of the ex vivo 
splenocyte system to predict immune responses.  
3.2. Evaluation of Cytokine Response to Immunomodulators 
Once it was confirmed that the EAE splenocyte screening system produced expected 
outcomes with control treatments, eleven immunomodulatory compounds were analyzed (Table 
2).  As elaborated upon in the Discussion section, a dose of 1 nM was chosen to screen the 
immunomodulators in the splenocyte system.  For each immunomodulator treatment the cellular 
metabolic activity and cytokine response both with and without PLP antigen rechallenge were 
measured and compared to the vehicle control (Figure 4).  Additionally, the immune response of 
each immunomodulator was compared to the immunostimulant control of LPS (Figure 5). 
Analysis of cellular metabolic activity indicated that the screen contained both compounds that 
increased and compounds that decreased cell metabolism at the 1 nM dose.  Rapamycin was 
found to decrease metabolic activity both with and without PLP rechallenge, while 
dexamethasone only decreased metabolism without rechallenge as compared to vehicle (Figure 
4A). Alternatively, curcumin and acetylsalicylic acid increased metabolism upon PLP 




The cytokine response to each compound during rechallenge with 25 µΜ PLP was analyzed 
by measuring TNF-α, IFN-γ, IL-2, and IL-10.  The majority of immunomodulator treatments 
resulted in increased TNF-α levels with 25 µM PLP as compared to the same treatment without 
antigen rechallenge (Figure 4B).  The three compounds that did not significantly increase TNF-α 
upon antigen rechallenge as compared to no rechallenge, dexamethasone, FK-506, and dimethyl 
fumarate, also significantly decreased TNF-α as compared to the vehicle control (Figure 4B).  
Dexamethasone and FK-506 were also found to decrease IFN-γ levels as compared to vehicle 
with PLP rechallenge, as did rapamycin and ibrutinib (Figure 4C).  Curcumin was found to 
increase IFN-γ both upon antigen rechallenge and as compared to the vehicle control (Figure 
4C).  Levels of TNF-α and IFN-γ were both shown to significantly decrease upon treatment with 
all immunomodulators as compared to LPS control (Figure 5B-C).   
Additionally, dexamethasone was found to increase IL-2 levels both upon rechallenge with 
25 μM PLP and as compared to the vehicle control (Figure 4D). Finally, the cytokine IL-10 was 
analyzed due to its association with the anti-inflammatory response.[45]  Only dexamethasone 
was shown to increase IL-10 levels both upon rechallenge with antigen and as compared to the 
vehicle control (Figure 4E).  
Although our screen at 1 nM was successful, we wanted to confirm that this was the most 
effective dose for two of the compounds with promising immune responses and low IC50 values, 
dexamethasone and rapamycin.  Five different concentrations of the compounds near the 
experimentally determined IC50 (Table 3) were tested and the resulting cytokine responses were 
measured (Figure 6).  While both rapamycin and dexamethasone decreased cellular metabolic 
activity at 1 nM as compared to the vehicle control (Figure 4A), the cytokine responses at these 




increased both IL-2 and IL-10 as compared to vehicle with PLP rechallenge, while lower 
treatment concentrations did not (Figure 6C-D). Additionally, no significant decreases in 
cytokine levels were shown with 1 nM rapamycin treatment (Figure 6).  
 
3.3.  Assesment of Cell Population Changes with Immunomodulators 
Several compounds which exhibited interesting effects on cell metabolism and cytokine 
response were further analyzed for changes in splenocyte cell populations, including 
dexamethasone, rapamycin, ibrutinib, dimethyl fumarate and the controls TGF-β, Pam2CSK4, 
and LPS.  Changes in the population of T-cells and B-cells with respect to the whole splenocyte 
population were evaluated by flow cytometry and observed by fluorescent microscopy (Figures 
7 and 8).  The dendritic cell (DC) population was also investigated; however, levels were not 
detectable (data not shown).   
The overall T-cell population, as indicated by CD3+ cells, was found to decrease upon 
dexamethasone and rapamycin treatments as compared to LPS without antigen rechallenge 
(Figure 7A).  In contrast to T-cell changes, both ibrutinib and TGF-β treatments were found to 
decrease B-cell populations upon antigen challenge as compared to LPS with PLP rechallenge 
(Figure 7B).  Additionally, the population of T-helper cells characterized by both CD3 and CD4 
surface markers was measured. Both dexamethasone and rapamycin were found to decrease the 
percent of CD3+CD4+ T-cells without PLP rechallenge as compared to LPS (Figure 7C, D).  
No statistical differences were found between the immunomodulator treatments and the vehicle 
control.  
Finally, the ratio of CD3+ T-cells to CD22+ B-cells was evaluated upon treatment with 




rechallenge with antigen as compared to LPS (Figure 8A).  This effect may also be visually 
observed in fluorescent imaging of the cell populations following treatments with vehicle (0.1% 
DMSO), dexamethasone, or LPS (Figure 8B).  
 
4. Discussion  
Several published studies have reported antigen rechallenge experiments using EAE 
splenocytes and a few other studies reported in vitro screening of immunomodulators to induce 
tolerance [38, 39, 42, 43].  To our knowledge this is the first paper to combine these two 
techniques in order to enhance discovery of treatments of EAE capable of skewing the antigen-
specific immune response towards markers of immune tolerance.  Several reports using EAE 
splenocytes ex vivo have suggested utilizing these cells may improve immunological relatability 
to the in vivo model, as studies have found corresponding immune responses both in vivo and ex 
vivo [22, 44].  Specifically, the studies presented here utilized a mixed cell system found to 
contain diverse populations of B-cells (CD22+), T-cells (CD3+), and T-helper cells 
(CD3+CD4+) to better mimic the immunological environment in vivo (Figures 7 and 8).  As 
compared to an in vivo study, the ex vivo screen utilized fewer animals and material to 
demonstrate immune responses. Overall, the complex immune environment of the spleen may 
serve as a bridge between in vitro immortalized cell lines and in vivo studies for drug screening. 
In order to evaluate the immune response to various treatments in the EAE splenocytes 
system, cellular assays were needed to measure both metabolic activity and cytokines responses.  
Cellular metabolic activity was primarily utilized as a measure of cell viability to ensure the 
compounds tested were not cytotoxic at the concentrations analyzed.  Four different cytokines, 




treatments as each of these cytokines has been shown to have important impacts on EAE, both in 
disease development and suppression.  Pro-inflammatory cytokines TNF-α and IFN-γ were 
measured as both have been found to indicate EAE pathogenesis [34, 46] and are characteristic 
of T-helper type 1 (Th1) activation, which is believed to be the primary cell type in development 
of EAE [45, 47].  The cytokine IL-2 plays a particularly interesting role in autoimmune 
pathology and treatment, as it has been indicated in both inflammatory T-cell and regulatory T-
cell (Treg) responses [45, 48].  Although increased concentrations of IL-2 have been found in 
MS patients indicating a pro-inflammatory activity, IL-2 has recently been shown to be 
necessary for the production of memory Tregs [48-51].  Finally, the cytokine IL-10 was chosen 
as a marker of immunosuppression and tolerance.  IL-10 has been shown to suppress the activity 
of effector T-cells and promote the expansion of Tregs in both EAE and MS [52].  Each assay 
was used to both establish the EAE splenocyte system as an ex vivo screening tool and to 
evaluate the immune response to various treatments.  
During development of the ex vivo screening assay using EAE splenocytes, we first 
confirmed the presence of an antigen-specific response ex vivo.  When comparing the immune 
response upon antigen rechallenge, EAE splenocytes were found to produce significantly higher 
cytokine responses upon PLP rechallenge as compared to no rechallenge (Figure 1).  Healthy 
splenocytes did not produce an antigen-specific response for any of the cytokines measured 
(Figure 1). Additionally, cytokine levels with PLP rechallenge were significantly increased in 
EAE mice as compared to healthy mice (Figure 1). These results demonstrate the importance of 
an antigen-educated system such as EAE splenocytes to produce an antigen-specific immune 




Following demonstration of antigen-specific responses in EAE splenocytes, several controls 
were tested in order to confirm the robustness of the ex vivo screening system (Figure 3). The 
controls chosen all had well established immune responses, both pro-inflammatory (imiquimod, 
Pam2CSK, and LPS) and anti-inflammatory (TGF-β) responses (Table 1).  LPS treatment is well 
known to increase pro-inflammatory cytokine production, including TNF-α and IFN-γ [45].  IL-2 
is most likely increased due to inflammatory T-cell proliferation following LPS activation, 
although this was only observed without antigen rechallenge (Figure 3D).  Although IL-10 is 
generally considered an anti-inflammatory cytokine, LPS treatment of EAE splenocytes 
increased IL-10 (Figure 3E).  LPS had been shown in literature to drastically increase IL-10 
levels in cells that have been ‘over-stimulated’ in order to control excessive immune activation, 
as may be the case when stimulating splenocytes with both PLP antigen and LPS [53, 54].  
Pam2CSK4 stimulates the immune response through toll like receptors in a similar mechanism to 
LPS [55] and therefore is associated with many similar pro-inflammatory responses, such as the 
increase in IFN-γ as compared to vehicle (Figure 3C).  
The concentration at which to screen small molecule immunomodulators was then 
determined through analysis of successful in vivo studies in literature and known IC50 
concentrations (Table 3). The compounds selected have all demonstrated tolerogenic potential in 
literature at in vitro doses ranging from 0.1 nM to 2.5 mM (Table 2).  For screening the 
compounds in our splenocyte system, a concentration was determined to best mimic the 
immunomodulator concentration that would be experienced by immune cells in secondary 
lymphoid organs following in vivo treatment while preventing significant cytotoxicity.  
Literature examining the in vivo doses of these immunomodulators reported effective tolerogenic 




microparticles or liposomes given subcutaneously [22, 24, 56].  The micromolar dosing of 
immunomodulator subcutaneously in particles has been found to correlate with ≤0.1% of total 
dose trafficking to secondary lymphoid organs such as the spleen [57, 58].  The reported in vivo 
doses and delivery vehicle distribution would suggest approximately 0.08 to 2 nM dose reaches 
splenocytes. Immunomodulator dose to these cells is important as the majority of antigen-
specific cell activation occurs in secondary lymphoid organs [31, 45].  
In addition, many of these compounds cause global immunosuppression at high 
concentrations, suggesting they should be given at lower doses to induce immune tolerance [59, 
60].  In order to prevent possible global immunosuppression and cellular cytotoxicity, the IC50 
for cellular metabolic activity was found in literature and in our splenocyte system for several 
compounds (Table 3).  Previous studies and knowledge of the IC50 concentrations led us to 
explore a dose of 1 nM.  Finally, further investigation of the dosing range of dexamethasone and 
rapamycin supported the selection of a 1 nM dose (Figure 6).  
Once the EAE splenocyte system was established as being antigen-specific, having 
reproducible immune responses, and an appropriate concentration was determined for small 
molecule immunomodulators, eleven compounds were screened for their ability to skew the 
antigen-specific immune response (Table 2).  Cell metabolism, cytokine response, and the 
change in effector cell populations with different treatments were investigated.  Several 
compounds demonstrated unique immune responses in the splenocytes, indicative of both 
successful and unsuccessful tolerogenic potential.  Dexamethasone, rapamycin, FK-506, 
ibrutinib, and dimethyl fumarate each demonstrated somewhat unique responses indicating a 
tolerogenic effect.  The other compounds screened (propargylglycine, simvastatin, 




differences as compared to the vehicle control, or resulted in a response that did not indicate 
immune tolerance.  
Overall, dexamethasone presented the most significantly different responses as compared to 
the vehicle control in all cytokines measured (Figure 4).  Dexamethasone also decreased both 
CD3+ and CD3+CD4+ T-cell populations as compared to LPS (Figure 7).  Significant decreases 
in both TNF-α and IFN-γ indicated the ability of dexamethasone to maintain immunosuppression 
even upon rechallenge with antigen (Figure 4 B, C).  Dexamethasone also increased both IL-2 
and IL-10 with PLP rechallenge and therefore potentially promoted an antigen-specific 
regulatory response (Figure 4 D, E).  These findings are consistent with previous studies, which 
have shown dexamethasone can increase tolerogenic cytokines and regulatory cell populations 
[12, 42, 61, 62].  Additionally, dexamethasone treatment decreased both CD3+ T-cell and 
CD3+CD4+ T-cell populations as compared to the immunostimulant LPS without antigen 
rechallenge (Figure 7 A, C, D).  With the increased IL-2, the population of T-cells would be 
expected to increase with dexamethasone treatment; however, it has been previously shown in 
literature that the presence of both dexamethasone and IL-2 in EAE shifts the T-cell population 
towards CD4+ Tregs while decreasing immunogenic CD4+ T-cells at a higher capacity, resulting 
in a net decrease in the CD4+ T-cell population [62, 63].  In contrast to the overall T-cell 
decreases, the ratio of CD3+ T-cells to CD22+ B-cells was found to increase upon treatment 
with dexamethasone as compared to LPS with PLP rechallenge (Figure 8).  Although 
historically considered to be a T-cell mediated disease, recently B-cells have been shown to play 
an important role in EAE and MS pathogenesis [64, 65].  The importance of B-cell populations 
in EAE was demonstrated in our results by the known tolerogenic cytokine TGF-β specifically 




depletion of B-cells has also been shown to be effective in treating MS, with several therapies 
targeting CD20+ B-cells (Rituximab, Ocrelizumab, and Ofatumumab) demonstrating efficacy in 
humans [66-68].  Overall, dexamethasone was the most effective at skewing the antigen-specific 
immune response of the compounds screened at a dose of 1 nM, and will be more deeply 
investigated in future studies. 
In addition to dexamethasone, the immunomodulators rapamycin, FK-506, ibrutinib, and 
dimethyl fumarate were all found to have effects on cell metabolism and cytokines indicative of 
antigen-specific immunomodulation and tolerance (Figure 4).  FK-506 was both found to 
decrease TNF-α and IFN-γ as compared to vehicle upon rechallenge with antigen (Figure 4 B, 
C).   These results consistent with the tolerogenic abilities FK-506 has demonstrated in literature, 
including the ability to expand Treg populations while decreasing immunogenic T-cell 
populations such as T-helper type 17 (Th17) cells [19].  Additionally, rapamycin, dimethyl 
fumarate, and ibrutinib were each found to decrease one pro-inflammatory cytokine, either TNF-
α or IFN-γ (Figure 4 B, C).   
Rapamycin was found to not only decrease pro-inflammatory cytokines as compared to 
vehicle, but also resulted in significant decreases in both CD3+ and CD3+CD4+ T-cell 
populations as compared to LPS (Figure 7A, C).   While these findings point towards strong 
anti-inflammatory activity, the decreased cellular metabolic activity at the same concentration 
(Figure 4A) may point to a mechanism based on cytotoxicity rather than immune modulation.  
Both measured and literature IC50 values for rapamycin fell below the screening concentration 
of 1 nM (Table 3). It is possible that either cell death or quiescence was occurring at this 
concentration.  When alternative rapamycin concentrations were studied, higher levels of TNF-α 




may be leading to decreased pro-inflammatory cytokine response. Rapamycin has previously 
been shown in literature to promote Treg expansion; however, it is possible that the decrease in 
cellular metabolic activity at 1 nM (Figures 4A) may have limited the ability for this 
proliferation to occur [69-71]. These results indicated that although 1 nM was a reasonable 
concentration for an initial screen, further analysis of compounds with low IC50s, such as 
rapamycin, may benefit from screening at a lower dose to fully understand their tolerogenic 
potential.  
Several of the other immunodulators screened, including propargylglycine, simvastatin, 
andrographolide, and monomethyl fumarate, resulted in no significant change in metabolism or 
cytokine response as compared to the vehicle control (Figure 4).  Additionally, the compounds 
curcumin and acetylsalicylic acid seemed to produce metabolic and cytokine responses, which 
opposed their tolerogenic potential reported in literature [72, 73].  Curcumin and acetylsalicylic 
acid were both found to increase cellular metabolic activity compared to vehicle and LPS 
controls with antigen rechallenge (Figure 4A and Figure 3A).  Curcumin was also found to 
display further pro-inflammatory characteristics by increasing IFN-γ levels as compared to 
vehicle (Figure 4C).  The lack of immunosuppression by curcumin may be due to the 1 nM 
dose, as previous studies have shown that in vitro doses of 1000 nM or greater are needed for 




In this chapter we demonstrated that splenocytes from EAE mice can be used as an effective 




model.  EAE splenocytes demonstrated antigen-specific immune responses through rechallenge 
with PLP antigen, and therefore offered a mechanism by which to screen immunomodulators for 
their ability to skew the antigen-specific immune response.  Of the eleven immunomodulators 
investigated, only dexamethasone increased tolerogenic cytokines, decreased pro-inflammatory 
cytokines, and decreased CD3+ and CD3+CD4+ T-cell populations at a relevant dose.  Further 
studies into other immunological markers and in vivo effects of dexamethasone are needed to 
confirm the ability to induce antigen-specific tolerance upon co-delivery with autoantigen.  
Additionally, further investigation is needed to determine if less potent compounds, such as 
curcumin and acetylsalicylic acid, have potential to skew the antigen specific immune response 
at higher concentrations.  Nevertheless, these ex vivo studies provide a foundation for the 
investigation of immunomodulators for use in antigen-specific treatment of autoimmunity, which 








Table 1. Controls with known Immune Response Used for Validation of Screen 





Produces a regulatory response by inducing Treg 
and tolerogenic DC production and suppression 
of inflammation [45, 75, 76] 
Imiquimod TLR7 
Immunostimulation and pro-inflammatory 




Immunostimulation and pro-inflammatory 
cytokine production [45] 
Pam2CSK4 TLR2 & TLR 6 
Immunostimulation and pro-inflammatory 


















Table 2. Immunomodulators Screened in EAE Splenocytes 
Compound Target Proposed Tolerogenic Functions 
Dosing range to 






 Induces Treg and tolerogenic DC 
proliferation [12, 42, 61, 62, 78] 
0.1 to 1000 [61, 62, 
78-80] 
Rapamycin mTOR pathway 
Suppresses IL-2 production, induces 
Treg proliferation [42, 43, 69, 81-83] 
10.9 to 100 [69, 70, 
81] 
FK-506 Calcineurin 
Suppresses IL-2 production, decreases 
Th17 response, induces Treg and 
tolerogenic DC proliferation [19, 84, 85] 





Induces IDO expression, induces Treg 
proliferation, induces production of IL-
10 and TGF-β [42, 87] 
4,800 to 10,000 [42, 
87] 




Suppresses IL-12 and IFN-γ production 
[89] 
Not reported in vitro 
Curcumin unknown 
Induces tolerogenic DC proliferation and 
IL-10 production [72, 74] 





Induces Treg and tolerogenic DC 
proliferation [73, 90] 




Inhibits APC migration, suppresses pro-
inflammatory cytokine production [92] 







Decreases oxidative stress and pro-
inflammatory cytokine production, 
induces Treg proliferation [93-95] 




Decreases oxidative stress, protects 
inflamed blood-brain barrier [93, 94, 96] 






Figure 1: Splenocytes were harvested from healthy and EAE mice and rechallenged with (black 
bars) or without (gray bars) 25 μM PLP antigen for 120 hours. A.) Cell metabolism via resazurin 
and supernatant cytokine levels of B.) TNF-α, C.) IFN-γ, D.) IL-2, E.) IL-10 were determined for 
healthy splenocytes and EAE splenocytes. (n=7 per group, * p<0.05 **p<0.01, ***p<0.001, 
**** p<0.0001 for healthy versus EAE splenocytes with comparisons to 25 µM PLP in black 
and no PLP in gray, # p<0.05 for 25 μM PLP versus no PLP, Black bars indicate with 25 μM 






Figure 2: Splenocytes were harvest from EAE mice and treated with and without 25 μM PLP 
rechallenge for 24, 48, 72, 96, 120, or 144 hours. A.) Cell metabolism via resazurin and 
supernatant cytokine levels of B.) TNF-α, C.) IFN-γ, and D.) IL-2 were determined.  All data 
was normalized to 120 hours without PLP rechallenge. The cytokine IL-10 was measured but not 
detectable at 120 hours without rechallenge, so data is not shown. (n≥5 per group; * p<0.05 
**p<0.01, ***p<0.001, **** p<0.0001 25 μM PLP versus no PLP rechallenge for each time-










Figure 3. Splenocytes were harvested from EAE mice and treated with a control compound for 
120 hours, with or without 25 µM PLP antigen rechallenge.  A.) Cell metabolism and 
supernatant cytokine levels of B.) TNF-α, C.) IFN-γ, D.) IL-2 and E.) IL-10 were determined.  
All data was normalized to vehicle control without PLP rechallenge. (n≥5 per group; * p<0.05 
**p<0.01, ***p<0.001, **** p<0.0001 for treatment group versus vehicle with comparisons to 
25 µM PLP in black and no PLP in gray, # p<0.05 for 25 μM PLP versus no PLP, ND indicates 
cytokine levels were not detectable, Black bars indicate with 25 μM PLP and Gray bars indicate 





Figure 4. Splenocytes were harvested from EAE mice and treated with either vehicle or an 
immunomodulatory compound at 1 nM for 120 hours, with or without 25 µM PLP antigen 
rechallenge.  A.) Cell metabolism and supernatant cytokine levels of B.) TNF-α, C.) IFN-γ, D.) 
IL-2 and E.) IL-10 were determined.  All data was normalized to vehicle control without PLP 
rechallenge. (n≥5 per group; * p<0.05 **p<0.01, ***p<0.001, **** p<0.0001 for treatment 
group versus vehicle with comparisons to 25 μM PLP in black and no PLP in gray, # p<0.05 for 
25 μM PLP versus no PLP, ND indicates cytokine levels were not detectable, Black bars indicate 





Figure 5. Splenocytes were harvested from EAE mice and treated with either vehicle or an 
immunomodulator at 1 nM for 120 hours, with or without 25 µM PLP antigen rechallenge.  A.) 
Cell metabolism and supernatant cytokine levels of B.) TNF-α, C.) IFN-γ, D.) IL-2 and E.) IL-10 
were determined.  All data was normalized to vehicle control without PLP rechallenge. (n≥5 per 
group; * p<0.05 **p<0.01, ***p<0.001, **** p<0.0001 for treatment group versus LPS control 
with comparisons to 25 μM PLP in black and no PLP in gray, # p<0.05 for 25 μM PLP versus no 
PLP, ND indicates cytokine levels were not detectable, Black bars indicate with 25 μM PLP and 




Table 3. Molecular weight and IC50 range, both from literature and experimentally determined 












IC50 Range from Literature in nM 
(Experimentally determined IC50 in EAE 
Splenocytes in nM) 
Dexamethasone 392.5 4 to 1,000 (5.0) [97-99] 
Rapamycin 914.2 0.2 to 0.5 (0.04) [100] 
FK-506 804.02 0.1 to 8.6 (0.2) [100-103] 
Simvastatin 418.6 170 to 35,300 (100) [104, 105] 
Andrographolide 350.45 1,000 to 6,000 (2,000) [106-108] 
Propargylglycine 113.11 >8.84 x 10^10 (>100,000) [109] 
Curcumin 368.38 5,500 to 11,600 [110] 
Acetylsalcylic Acid 180.16 100,000 [111] 
Ibrutinib 440.50 2.0 to 6,400 [92, 112-114] 
Dimethyl fumarate 144.13 2,300 to 2,500 [93, 115] 





Figure 6. Splenocytes were harvest from EAE mice and treated with different concentrations of 




Concentrations around the IC50 (5 nM-0.001 nM) were analyzed and supernatant cytokine levels 
of A.) TNF-α, B.) IFN-γ, C.) IL-2, and D.) IL-10 were determined. All data was normalized to 
vehicle control without PLP rechallenge. (n≥5 per group; * p<0.05 **p<0.01, ***p<0.001, **** 
p<0.0001 for different treatment concentrations versus vehicle with comparisons to 25 μM PLP 
in black and no PLP in gray, # p<0.05 for 25 μM PLP versus no PLP, Black bars indicate with 





























Figure 7. Splenocytes were harvested from EAE mice and treated with vehicle, an 
immunomodulator at 1 nM, or a control compound for 120 hours, with or without 25 µM PLP 
antigen rechallenge.  The treated cells were then stained with antibodies for CD3 (Alexa Fluor 
488), CD22 (Alexa Fluor 647), and CD4 (R-phycoerythrin) and analyzed by flow cytometry.  
Cell populations were determined for A.) T-cells (CD3+), B.) B-cells (CD22+), and C.) T-helper 
cells (CD3+CD4+) as a percentage of the total cell population.  D.) Representative flow 
cytometry data demonstrates the CD3+CD4+ population trends observed in the splenocytes.  
(n=4 per group; * p<0.05 **p<0.01, ***p<0.001, **** p<0.0001 for different treatments versus 
LPS control with comparisons to 25 μM PLP in black and no PLP in gray, # p<0.05 for 25 μM 







Figure 8. Splenocytes were harvested from EAE mice and treated with either vehicle, an 
immunomodulator at 1 nM, or a control compound for 120 hours, with or without 25 µM PLP 
antigen rechallenge.  The treated cells were then stained with antibodies for CD3 and CD22. The 
ratios of T-cells (CD3+) to B-cells (CD22+) for each treatment was determined by A.) flow 
cytometry.  B.) Representative images are shown from vehicle (0.1% DMSO), dexamethasone, 
and LPS treatment groups all rechallenged with 25 µM PLP.  Images indicate cell nuclei 
(Hoechst), T-cells (green, Alexa Fluor 488), and B-cells (blue, Alexa Fluor 647). (n=4 per group, 
* p<0.05 for different treatments versus LPS control with comparisons to 25 μM PLP in black 
and no PLP in gray, Black bars indicate with 25 μM PLP and Gray bars indicate no PLP, Scale 
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Chapter IV: Co-Delivery of Autoantigen and 
Dexamethasone in Incomplete Freund’s Adjuvant 




















The current therapies for autoimmune diseases, including multiple sclerosis (MS), are often 
unsuccessful in stopping or reversing disease progression and may lead to non-specific 
immunosuppression [1, 2]. Effective antigen-specific immunotherapy (ASIT) has the potential to 
suppress the immune response in regards to a specific autoantigen, and therefore would not 
hinder the ability of the patient’s immune system to fight off foreign pathogens. Unfortunately, 
attempts to create ASIT for autoimmunity using only autoantigen have largely been unsuccessful 
[3-5].  In recent years, the idea of combining autoantigen and immunomodulators has emerged as 
a way to improve upon ASIT for autoimmunity [6].  Promising research has indicated that co-
delivery of a small molecule immunomodulator with an autoantigen can lead to the creation of 
antigen-specific treatment of autoimmune disease [7-11]. 
Co-delivery of autoantigen and immunomodulator has been successful in animal models of 
autoimmunity [7-14].  These promising results may be due to the importance of having the 
components combined both spatially and temporally to elicit the appropriate antigen-specific 
immune response.  In fact, traditional vaccines have utilized co-delivery of antigen and 
immunomodulator (i.e., adjuvant) to successfully induce a protective antigen-specific response 
[15].  One hypothesized mechanism responsible for the success of co-delivery is the ability to 
mimic the natural two-signal paradigm of antigen-specific immunity, wherein concurrent antigen 
and a secondary signal (co-stimulatory or co-inhibitory) are needed to elicit an antigen-specific 
immune response [15, 16]. In this regard, several studies have explored co-delivery of 
autoantigen and immunomodulator that allow for the controlled release of one or both 




which is known to contribute to efficacy of antigen-specific responses in autoimmune models [7-
11, 15].  
The potential to mimic vaccine mechanisms, not only through antigen and adjuvant co-
delivery but also through induction of humoral or T-helper type-2 (Th2) immunity, has shown 
efficacy in the treatment of T-helper type-1 (Th1) related autoimmune diseases.  Both MS and 
the murine model of the disease, experimental autoimmune encephalomyelitis (EAE), are 
believed to be primarily Th1 and Th17-mediated [17, 18].  Utilizing an adjuvant initially 
developed for protective vaccination against foreign pathogens, incomplete Freud’s adjuvant 
(IFA), studies have shown a shift from a Th1/Th17 to a Th2/humoral response to autoantigen 
resulting in the suppression of autoimmune disease in animals [19, 20].  IFA is composed of 85% 
mineral oil (paraffin oil) and 15% emulsifier (mannide monooleate), and a 1:1 emulsion of IFA 
with an aqueous solution containing antigen has been shown to enhance the antigen-specific 
immune response in animals [16, 21, 22].  Additionally, IFA emulsions both alone and in 
combination with autoantigen have demonstrated the capacity to mitigate symptoms of 
autoimmune disease [19, 20, 23-28].  A recent clinical trial has also shown the ability of IFA to 
deliver autoantigen for the treatment of type 1 diabetes in humans [29]. 
Recently our lab has found that IFA has the ability to co-deliver dexamethasone (DEX) and 
water-soluble antigen without increasing pro-inflammatory responses in dendritic cells (Antunez 
et al, Manuscript in Progress).  Although traditionally thought of as a general 
immunosuppressant, DEX has been shown to be an effective immunomodulator with the ability 
to decrease the Th1 response, enhance the Th2 response, and even skew the immune system 




immunomodulators in antigen-specific splenocytes obtained from EAE mice, and determined 
that DEX is capable of suppressing pro-inflammatory Th1-related cytokines, increasing 
regulatory cytokines, and decreasing the overall T-cell response (Northrup et al, Submitted 
Manuscript). Other groups have tested the co-administration or co-delivery of dexamethasone 
and autoantigen in animal models of autoimmunity with successful outcomes [9, 35].  
We investigated the co-delivery of DEX and proteolipid protein epitope (PLP139-151), the 
antigen used to induce EAE, with an IFA emulsion.  Additionally, all individual components of 
the co-delivery system and their possible combinations were investigated (Table 1) for the 
treatment of EAE.  To our knowledge, this is the first study demonstrating the use of IFA for co-
delivery of an immunomodulator and autoantigen for autoimmune therapy.  Our approach seeks 
to expand upon current knowledge of co-delivery in ASIT immunotherapy, the unique immune 
effects of IFA, and the immunomodulatory mechanisms of DEX in order to create an antigen-
specific therapy for autoimmunity. 
 
2. Materials and Methods 
 
2.9 Materials.  The peptide antigen, PLP139-151, was obtained from PolyPeptide Laboratories 
(Torrance, CA).  For EAE induction incomplete Freund’s adjuvant (IFA) and killed 
Mycobacterium tuberculosis strain H37RA were purchased from Difco (Sparks, MD), and 
pertussis toxin was purchased from List Biological Laboratories (Campbell, CA).  
Dexamethasone (DEX) was purchased from Sigma-Aldrich (St. Louis, MO). For flow 
cytometry studies, Alexa Fluor 488- conjugated anti-mouse CD3, Alexa Fluor 647-
conjugated anti-mouse CD19, and Pacific Blue-conjugated anti-mouse CD11c, and their 




chemicals and reagents were analytical grade and used as received. 
2.10 Preparation of IFA emulsion. All IFA emulsions were created with a 1:1 volumetric 
ratio of IFA to phosphate buffered saline (PBS).  Before emulsification, the PLP peptide was 
solubilized in PBS at 2x the final concentration of 2000 µM.  Dexamethasone was first 
dissolved in DMSO and added to the PBS phase before emulsification such that the final 
amount of DMSO was less than 0.5% (the maximum concentration recommended by ICH 
Guideline, Impurities: Guideline for Residual Solvents, Q3C (R5), 2011) and the final 
concentration of DEX was 20 µg/ml. The IFA and PBS phases were then emulsified using a 
20 gage micro-emulsifying needle (stainless steel, 20G X 2-7/8” with reinforcing bar, 
Cadence Science, Inc.) using two 6 cc plastic syringes, and the emulsion was passed through 
the needle 15 times. For in vivo treatments, IFA emulsions were vortexed (speed 10, Mini 
Vortexer, Fisher Scientific) for 3 min immediately prior to injection. 
2.11 Characterization of PLP and DEX Release.  For the release characterization, 4 mL of 
the IFA emulsion was placed into regenerated cellulose dialysis bags with 6,000-8,000 
MWCO (30μm wall thickness, Fisherbrand Dialysis Tubing) which was then placed into 100 
mL of PBS in a glass beaker.  Alternatively, PLP and DEX were also placed in PBS at the 
same concentration as in the final emulsion, and release was characterized via the same 
procedure.  All release studies were kept at 37ºC on an incubator shaker (79 rpm, Excella 
E24 Incubator Shaker, New Brunswick Scientific), and 1 mL samples were taken at specific 
time points; with 1 mL of PBS re-added at each time point.  Characterization of the PLP and 
DEX concentrations released from the dialysis bags were performed using gradient reverse-
phase HPLC (Waters 2796 Bioseparations Module, Waters Corp) on a C4 analytical column 




Samples were eluted using mobile phases A (100% water with 0.1% trifuoroacetic acid 
(TFA)) and B (100% acetonitrile with 0.1% TFA) with a gradient of 100% A to 20% A over 
25 min at a constant flow of 1 ml/min. Mobile phase compositions were (A) 100% water 
with 0.1% TFA and (B) 100% acetonitrile with 0.1% trifluoroacetic acid (TFA).  PLP was 
detected at 220nm and DEX was detected at 240nm with a dual wavelength absorbance 
detector (Waters 2487 Dual λ Absorbance Detector, Waters Corp). Data was collected and 
processed using Empower 3 Software (Waters Corp).  
2.12 Induction of EAE and Therapeutic Study.  Single step SJL/J female mice, 4 – 5 weeks 
old, were purchased from Envigo Laboratories and housed under specified, pathogen-free 
conditions at The University of Kansas. All protocols involving live mice were approved by 
The University of Kansas Institutional Animal Care and Use Committee.  Mice were 
immunized subcutaneously with 200 µg of PLP139–151 in a 0.2 mL emulsion composed of 
equal volumes of PBS and IFA containing killed Mycobacterium tuberculosis strain H37RA 
at a final concentration of 4 mg/mL. The PLP139–151/CFA was administered to regions above 
the shoulders and the flanks (total of four sites; 50 μL at each injection site). In addition, 100 
µL of pertussis toxin (200 ng) was injected intraperitoneally on the day of immunization (day 
0) and 2 days post-immunization. Each treatment group contained six mice, except for the 
group with PLP treatment, which only contained five mice due to an unexpected death before 
disease induction. Mice received 100 µL subcutaneous injections at the nape of the neck on 
days 4, 7, and 10 of the study.  All DEX-containing treatment groups were given at 20 µg 
DEX per injection and all PLP-containing treatments groups were given 200 nmol PLP per 
injection. Disease progression was evaluated using clinical scoring as follows: 0, no clinical 




paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, 
paraplegia with forelimb weakness or paralysis; and 5, moribund.  Body weight was also 
measured daily.  
2.13 Splenocyte Isolation and ex vivo treatment.  Mouse spleens were resected from EAE 
mice on Day 25 following disease-induction and cultured as previously described [13].  
Briefly, the spleens were first passed through a wire mesh using the rubber end of a sterile 1 
mL syringe plunger, and collected in 5 mL of RPMI 1640 media.  The crude cellular extract 
was then centrifuged and the resulting cell pellet was resuspended in 3.5 ml of 1x Gey’s lysis 
solution and placed on ice for 3.5 minutes to lyse splenic red blood cells.  The lysis reaction 
was stopped by the addition of 10 ml RPMI 1640 media containing 10% FBS and 
centrifuged at 1,100 x g for 5 minutes.  The remaining cell pellet was resuspended in fresh 
media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and seeded 
in 96-well cell culture plates at a cell density of 1x106 cells/well in a final volume of 200 
µl.  The cells were immediately rechallenged with and without 25 µM PLP antigen.  
Stimulated cell cultures were incubated for 120 hours at 37°C in a CO2 (5%) incubator.  
2.14 Measurement of Cytokines. Supernatants of cell cultures were collected after 120 hour 
incubation post day 25 spleen harvest. Secreted cytokines; GM-CSF, TNF-α, IL-2, IFN-γ, IL-
10, IL-17, IL-15, and IL-23 were detected using a U-Plex assay kit according to 
manufacturer instructions (Meso Scale Discovery). Briefly, each U-Plex was coated with 50 
μL of the multiplex coating solution containing linker and biotinylated capture antibody 
combinations for each cytokine and incubated on a shaker at 700 rpm for 1 hour at room 
temperature. Following washing each well 3 times with 150 μL PBS containing 0.05% 




for 1 hour on a shaker at room temperature.  Detection antibody was added at 50 µL/well and 
incubated for 1 hour.  Finally, each assay plate was read using the QuickPlex multiplex plate 
reader (Meso Scale Discovery).  
2.15 Measurement of Cellular Metabolism. Cell metabolism was determined by a resazurin 
(7-hydroxy-3H-phenoxazin-3-one 10-oxide) assay. Briefly, resazurin (75 µmol/L final) was 
added to splenocyte cultures and incubated for 3 hours. Metabolic reductive capacity was 
determined by a change in fluorescence (excitation 560/emission 590). Background 
fluorescence was determined in RPMI media and was subtracted from each experimental 
read. All fluorescent readings were performed using a Spectramax M5 (Molecular Devices) 
plate reader. 
2.16 Fluorescent staining and Flow Cytometry. Immediately after isolation, splenocytes 
were seeded in 12-well cell culture plates at a cell density of 5x106 cells/well in a final 
volume of 1.5mL. Treatments were then given at the concentration of interest, both with and 
without 25 µM PLP.  Stimulated cell cultures were incubated for 120 hours at 37°C in a CO2 
(5%) incubator. At 120hrs, splenocytes were stained with the desired antibodies. Briefly, 
1x106 cells were washed with 1mL of wash buffer (RPMI 1640 media containing 5% FBS) 
before centrifugation and resuspension in 50 µL block buffer containing 20ug/ml TruStain 
fcX (anti-mouse CD16/32 antibody, Biolegend) in wash buffer.  Cells were incubated on ice 
for 25 minutes before adding the desired antibodies or isotype controls in 50 µL at 2x the 
manufacturer recommended concentration for 1 hour.  For flow cytometry analysis, 40,000 
cells per sample were detected using a BD FACSFusion cytometer. Data was analyzed using 
FlowJo Software. 




were coated with 50 µg/ml PLP in 100 µl of PBS and incubated overnight at 4°C.  The PLP 
coating solution was discarded and the plate was blocked with PBS containing 0.5% FBS for 
1 hour prior to addition of splenocytes.  Immediately after their isolation, splenocytes were 
seeded onto the coated 96-well plate at a cell density of 1x106 cells per well in a final volume 
of 100 μL. The splenocyte cultures were incubated for 48 hours at 37°C in a CO2 (5%) 
incubator.  Following incubation, each plate was washed 4x with PBS containing 0.05% 
Tween 20 for 2 min, followed by washing 2x with PBS for 2 min.  100 µL of horseradish 
peroxidase (HRP) conjugated anti-mouse IgG at a concentration of 1 µg/mL was added to 
each well and incubated for 1 hour at 37°C. Following a second wash step, identical to 
previously described, a buffer containing TrueBlue Peroxidase Substrate (Kirkegaard & 
Perry Laboratories, Inc) and agarose (1:1 ratio) was heated in a water bath to 56°C and 100 
µL was added to each well using reverse pipetting to avoid bubbles.  Plates were incubated 
overnight at 4°C before reading on the CTL Ultimate S6 ImmunoSpot Analyzer (Cellular 
Technology Limited). Analysis of spots was done using CTL ImmunoSpot software (Cellular 
Technology Limited.  
2.18 Statistical analysis. Statistical evaluation of data was performed using a one-way or two-
way analysis of variance (ANOVA) as experimentally appropriate, followed by Tukey and 
Sidak multiple comparison tests. Trends were described following individual t-tests and 
linear regression analysis. A single outlier was removed from the cytokine analysis of the 
IFA with Dex and PLP group (Figure 5) following outlier confirmation via the Grubb’ 
Outlier Test.  The criteria for statistical significance for all analyses was set at p<0.05. The 
majority of analyses were performed using GraphPad Software (GraphPad Software Inc.) and 





3.1. Characterization of IFA Emulsion containing PLP and Dex 
IFA oil was combined at a 1:1 ratio with phosphate buffered saline (PBS) containing PLP 
and DEX in order to create the IFA emulsion for co-delivery of autoantigen and 
immunomodulator.  The release of both PLP and DEX from either the IFA emulsion or PBS was 
measured by placing each formulation into a dialysis membrane (6,000-8,000 molecular weight 
cutoff) and tracking the release into sink conditions of PBS at 37ºC.  PLP and DEX were found 
to be fully released from PBS within the membrane after 24 hours and 10 hours, respectively 
(Figure 1).  DEX within the IFA emulsion was not fully released until approximately 120 hours 
(Figure 1A). PLP was much slower to release from the IFA emulsion, with less than 10% of the 
total PLP in the formulation being released within 192 hours (Figure 1B).  
3.2. Treatments containing PLP delivered in IFA Suppress EAE Symptoms 
IFA emulsion containing PLP and DEX, along with each combination of the components and 
a PBS control, were tested in mice with EAE (Table 1).  Treatments were given subcutaneously 
between the shoulder blades on Days 4, 7, and 10 of the study (as shown on Figure 2A-B and 
Figure 3A-B).  By day 12, half of the mice in the PBS control group had died.  Due to these 
deaths, and the corresponding disease score of 5, the PBS was statistically significant from all 
other treatments, including the IFA vehicle control, on at least one day of the study (Figure 2A-
B).  Additionally, due to the high error in clinical score associated with the days in which the 
PBS mice died (Days 11-12), the IFA is shown as an alternative control compared to all other 
treatments (Figure 2).  Weight changes were also monitored throughout the study and are shown 
as a percent change as compared to day 8, the last day with no disease symptoms (Figure 3). 




score, the weight change was unaffected.  In fact, there was no statistical difference between IFA 
and PBS treatment groups in terms of weight change (Figure 3A). 
In order to determine the benefits offered by co-delivery of autoantigen and 
immunomodulator, co-delivery of IFA with DEX + PLP was also compared to the clinical score 
and change in weight from each treatment group (Figures 2 & 3).  IFA with DEX + PLP 
significantly decreased clinical score and weight change as compared to PBS on three days of the 
study (Figure 2B & Figure 3B). Interestingly, as compared to IFA alone, IFA with DEX + PLP 
decreased the both clinical score and weight change during days before, during, and after peak 
disease (as determined by peak clinical scores and maximum weight change, see Table 1) 
(Figure 2C & Figure 3C).  IFA with DEX + PLP also significantly suppressed disease 
symptoms on at least one day during the study as compared to DEX only, IFA with DEX, and 
DEX + PLP (Figure 2D, F, H).  Treatments that were not statistically different than IFA with 
DEX + PLP; both PLP and IFA with PLP, decreased clinical scores as compared to IFA only 
(Figure 2 E, G).  All of these treatments (PLP, IFA with PLP, and IFA with DEX + PLP) also 
significantly decreased the peak clinical score as compared to the PBS control (Figure 4A).  
Interestingly, both IFA with DEX + PLP and IFA with PLP suppressed EAE symptoms to a 
similar degree.  The suppression by both treatments containing PLP in IFA is most clearly 
observed by examining the area under the curve for clinical score and peak clinical disease score 
(Figure 4B).  Surprisingly, this same trend was not seen in weight change data, as IFA with PLP 
actually had significantly more weight loss as compared to IFA with DEX + PLP around the 




3.3. Dexamethasone Shifts Cytokine Profiles Away from Inflammation 
Following disease remission, on day 25 of the EAE study splenocytes were collected from 
the mice and were rechallenged in vitro with and without PLP antigen.  Cellular metabolic 
activity and cytokine responses were measured at 120 hours post-rechallenge (Figure 5).  
Metabolic activity was found to significantly increase with DEX treatment as compared to IFA 
only, IFA with DEX, and IFA with DEX + PLP without rechallenge and increased metabolic 
activity both with and without rechallenge as compared to PLP treatment (Figure 5A).  DEX + 
PLP was also found to increase metabolic activity via measurement of resazurin as compared to 
PLP only with antigen rechallenge (Figure 5A).  
Rechallenge with PLP was found to significantly increase the cytokine levels of GM-CSF, 
IFN-γ, TNF-α, IL-6, and IL-4 for the majority of treatment groups and increased levels of IL-10, 
IL-17, IL-23, and IL-15 in some of the treatment groups (Figure 5).  Significant differences 
between the treatment groups were found in the cytokine response of GM-CSF, IFN-γ, IL-6, IL-
4, and IL-23; however, differences were only found for samples with PLP rechallenge.  
Treatments containing DEX tended to decrease pro-inflammatory cytokines including GM-CSF, 
IFN-γ, and IL-23 as compared to other treatment groups upon rechallenge with PLP (Figure 5B, 
C, J).  Both IFA and PLP only treatments were found to significantly increase the pro-
inflammatory GM-CSF as compared to IFA with DEX and IFA with DEX + PLP (Figure 5B).  
IL-23 also significantly increased due to treatment with PLP, this time compared to DEX and 
IFA with DEX (Figure 5J).  Surprisingly, the general pro-inflammatory cytokine IFN-γ was 
shown to increase with IFA with PLP, a treatment that was effective at suppressing clinical score 




only, DEX + PLP, and IFA with DEX + PLP (Figure 5C). IL-6 was shown to be significantly 
increased with DEX treatment as compared to IFA with DEX and IFA with DEX + PLP (Figure 
5F).  Unlike the majority of cytokines analyzed, IL-4 significantly increased with PBS treatment 
as compared to all other treatment groups (Figure 5I).  
3.4. Effective in vivo Therapies Increase B-cell-related Responses in Splenocytes 
In addition to cytokine responses, changes in cell populations in the splenocytes obtained 
from the different in vivo treatment groups were examined both with and without PLP antigen 
rechallenge (Figure 6).  The population of T-cells, as identified by CD3, was found to be 
statistically similar for all treatment groups, both with and without rechallenge (Figure 6A). 
CD11c, which is a common marker for dendritic cells (DCs), was found to be increased both 
with and without antigen rechallenge for IFA with DEX + PLP and with antigen for IFA with 
PLP (Figure 6B). B-cells, as identified by CD19, were found to be significantly increased in the 
IFA with DEX+ PLP treatment group (Figure 6C, F).  CD19+CD11c+cells were also analyzed, 
as these cells have been shown to act as autoimmune associated B-cells (ABCs) [36, 37]. 
CD19+CD11c+ population was significantly increased for the IFA with DEX + PLP treatment 
group without antigen rechallenge (Figure 6D).  The ABC population in the IFA with DEX + 
PLP group was significantly higher than all other treatment groups as a percent of the total 
splenocytes; however, the ABCs were not increased as a percentage of the B-cell (CD19+) 
population (Figure 6E).  
Autoantibody production was also measured using ELISPot to determine the number of cells 
producing PLP-specific antibodies in the spleen following each in vivo treatment.  Similar to the 




higher anti-PLP antibody producing cells in splenocytes from mice treated by IFA with DEX + 
PLP as compared to other treatment groups (Figure 7).   
 
4. Discussion  
The combination of autoantigen and immunomodulators has recently emerged as a 
potentially effective ASIT strategy for the treatment of autoimmunity [6].   In this study, IFA 
was investigated as a co-delivery vehicle in order to treat EAE with a combination of DEX and 
PLP.  Our studies demonstrate that controlled release of DEX and PLP from IFA may provide 
optimal efficacy in suppressing EAE.  In particular, the release of PLP into solution was greatly 
slowed when it was emulsified into IFA (Figure 1B) and controlled release decreased disease 
severity in therapies containing PLP in an IFA emulsion (Figures 2 & 4B). IFA has been 
previously indicated to have significant immunosuppressive properties alone [26]; however, we 
did not observe this phenomenon.  IFA suppressed disease symptoms as compared to the PBS 
control on only one day, which was seen for all other treatments (Figure 2A). When used as a 
delivery vehicle for autoantigen or immunomodulator, IFA containing PLP resulted in the most 
pronounced disease suppression (Figures 2 & 4B). These results were surprising in that co-
delivery of DEX and PLP in IFA did not suppress disease clinical scores to any noticeable extent 
as compared to IFA with only PLP (Figure 2G and Figure 4B).  The slow release of PLP from 
the IFA emulsion may be extending the exposure of autoantigen to antigen-presenting cells, 
allowing the therapy to influence the immune system long after the injections. Previous studies 




autoantigen increases disease suppression both with and without an immunomodulatory signal 
[7, 8, 11, 38-40].  
We also observed that treatments containing PLP, even without controlled release, 
significantly decreased peak clinical score (Figure 4A) and seemed to delay disease onset 
(Figure 4C).  Treatment with an appropriate dose of autoantigen has often been reported to 
decrease autoimmune symptoms in animals, but has not been successfully translated to the clinic 
[3, 41].  The clinical efficacy of this treatment was also contradictory to the cytokine response 
observed in splenocytes obtained on day 25 of the study.  Treating EAE mice with PLP alone 
was shown to promote pro-inflammatory cytokine production by significantly increasing GM-
CSF and IL-23, and slightly increasing IFN-γ and IL-2 although not to a significant degree 
compared to other treatments (Figure 5). The correlation of the poor efficacy of autoantigen 
alone in humans with the increased pro-inflammatory cytokine production by PLP treatment 
emphasizes the importance of analyzing the immune response in addition to clinical symptoms in 
EAE.   
The in vivo data indicated the importance of controlled release of autoantigen in the creation 
of effective ASIT, while the addition of an immunomodulator such as DEX had little effect on 
clinical symptoms (Figure 2 & 3).  When analyzing the immune response more closely, it was 
found that DEX does play an important role in shifting the cytokine profile away from pro-
inflammatory Th1/Th17 responses (Figure 5).  Decreased pro-inflammatory cytokine levels 
were in direct contrast with an increase in cellular metabolic activity upon DEX treatment, 
therefore the suppression of pro-inflammatory cytokine by DEX may be even more significant 




to increase IL-6 (Figure 5F); however, this cytokine can be indicative of both pro-inflammatory 
(Th17) and regulatory (Treg) immune responses depending on the presence of other cytokine 
responses [42, 43].  The increase in IL-6 coupled with a decrease in IL-23 and GM-CSF, along 
with no change in IL-17, suggests that DEX is not producing a Th17 response and therefore IL-6 
production may not be indicative of inflammation [42, 43].  Another cytokine demonstrating 
unexpected results was IL-4, which was shown to decrease with all therapies, even IFA alone 
(Figure 5I); however, the role of IL-4 in the treatment of EAE has been debated [44]. 
Interesting immunological trends due to DEX treatment were also observed in the CD11c+ 
dendritic cell (DC) population upon rechallenge with PLP antigen (Figure 6B).  IFA with DEX 
and IFA with DEX + PLP significantly increased the population of DCs compared to the 
majority of treatments, and DEX + PLP increased DCs as compared to PLP only treatment. The 
increase of DCs with treatments containing DEX is directly reverse of the trend for DEX to 
decrease GM-CSF (Figure 5B).  GM-CSF has been known to be essential for the generation of 
inflammatory DCs from monocytes in the spleen, and plays a crucial role in EAE pathogenesis 
[45]. The inversely proportional trend of GM-CSF and CD11c+ DCs following treatments with 
DEX may indicate that the DCs being produced are not pro-inflammatory, and may actually be 
immature or even tolerogenic [46, 47]. CD11c+ DCs have been shown to act as tolerogenic DCs 
in the spleen [46]. Also, the treatment of DCs with DEX has previously been shown to produce 
higher levels of tolerogenic DCs [45, 48-50].  Additionally, although not statistically significant, 
a trend in the decrease of CD3+ T-cells with the addition of DEX was also noted (Figure 6A).  
Previous studies co-administering IFA and autoantigen have shown that a shift towards a 




diseases [19, 20].  Our study supported this hypothesis by demonstrating increased autoantibody 
production and increase B-cell populations in splenocytes from mice treated with either IFA with 
PLP or IFA with DEX + PLP (Figures 6 & 7).  Although IFA with DEX + PLP increased the 
percent of autoimmune associated B-cells (ABCs) in the entire splenocyte population, this trend 
appeared to be associated with an increase in B-cells overall rather than an increase in the 
proportion of B-cells that are ABCs (Figure 6D, E). Both B-cell and ABC populations were 
found to significantly decrease upon rechallenge with antigen.  Unresponsiveness to antigen 
rechallenge may indicate that many of these cells are anergic and therefore not contributing to 
EAE progression [51, 52].  
In measuring PLP-specific autoantibody producing B-cells via ELISpot, we discovered that 
the treatments that suppressed clinical symptoms of EAE had much higher levels of PLP-specific 
antibodies (Figure 7).  Increased production of antibody following effective treatment with IFA 
and autoantigen has been observed before in both human autoimmunity and animal models [20, 
29]. This increase in antibody production against autoantigen has been found to directly 
correspond to skewing the immune response towards a Th2/humoral response resulting in 
suppression of Th1/Th17-mediated autoimmunity [20].  Our results demonstrating both an 
increase in the B-cell population and PLP-specific antibody production with IFA with DEX + 
PLP treatment of EAE strongly support the hypothesis that the clinical disease suppression is due 






As the combination of autoantigen and immunomodulator gains more traction as an effective 
autoimmune therapy, it is important to understand how each component contributes to the 
desired outcome.  By investigating all possible treatment combinations of DEX and PLP using 
IFA as a delivery vehicle, we were able to identify some interesting trends in the treatment of 
EAE.  Although co-delivery of DEX and PLP was hypothesized to be most effective, it was 
found that IFA with PLP was just as efficacious at ameliorating disease symptoms in vivo.  Upon 
closer analysis of the immunological responses, it was found that DEX plays an important role in 
decreasing pro-inflammatory cytokines and possibly increasing tolerogenic DCs.  Additionally, 
the co-delivery treatment of IFA with PLP and DEX was shown to increase humoral responses 
through increased B-cell and antibody production.  A shift towards a humoral response is 
associated with a therapeutic efficacy in the treatment of EAE and MS. Overall, this data 
indicates that co-delivery of PLP autoantigen and DEX in an IFA emulsion is effective in the 














Table 1. in vivo Treatment Groups 
Treatment Groups 
Mice Alive 
at end of 
Study 
Mice without Severe 
Disease Symptoms 
(score < 2) 
Day of Peak 
Disease Score 
(Mean ± SD)a 
Day of Maximum 
% Weight Change 
(Mean ± SD)a 
PBS 3/6 1/6 12.3 ± 1.0 11.8 ± 1.3 
IFA 6/6 0/6 13.3 ± 0.5 12.0 ± 1.3 
DEX 6/6 0/6 12.2 ± 1.5 12.0 ± 0.9 
PLP 5/5 1/5 14.6 ± 4.7 15.0 ± 4.5 
IFA with DEX 6/6 1/6 12.5 ± 1.4 12.5 ± 1.4 
IFA with PLP 6/6 6/6 11.3 ± 1.4 11.7 ± 0.5 
DEX + PLP 6/6 2/6 13.0 ± 1.1 13.7 ± 0.8 
IFA with DEX + PLP 6/6 6/6 13.2 ± 1.9 13.3 ± 1.6 











Figure 1. Release at 37ºC of A.) DEX and B.) PLP from IFA emulsion (open circle) and PBS 
(black square) formulation within dialysis bag in sink conditions of PBS. Concentrations 
determined at each time point via RP-HPLC. Data shown as a percentage of total DEX or PLP in 






Figure 2. Clinical disease scores in EAE mice given components of co-delivery treatment, IFA 
with DEX + PLP. Disease score with PBS control treatment compared to A.) IFA and B.) IFA 
with DEX + PLP.  IFA and IFA with DEX + PLP treatments were compared to C.) each other, 
D.) DEX treatment, E.) PLP treatment, F.) IFA with DEX, G.) IFA with PLP and H.) DEX + 
PLP. All treatments were given on Days 4, 7, and 10 (black arrows). (n = 5-6 mice per group, * 











Figure 3. Percent change in weight as compared to day 8 (last day before symptoms) in EAE 
mice given components of co-delivery treatment, IFA with DEX + PLP. Percent weight change 
with PBS control treatment compared to A.) IFA and B.) IFA with DEX + PLP.  IFA and IFA 
with DEX + PLP treatments were compared to C.) each other, D.) DEX treatment, E.) PLP 
treatment, F.) IFA with DEX, G.) IFA with PLP and H.) DEX + PLP. All treatments were given 
on Days 4, 7, and 10 (black arrows). (n = 5-6 mice per group, * p< 0.05 as compared to IFA, # 











Figure 4.  The effect of in vivo treatments on EAE was also analyzed by comparing the A.) peak 
clinical score, B.) area under the curve for clinical scores, C.) and the incidence of disease. EAE 
disease incidence was evaluated such that disease free animals maintained a clinical score < 1. (n 











Figure 5. Splenocytes were harvested on day 25 from EAE mice treated in vivo with components 
of co-delivery treatment, IFA with DEX + PLP.  Splenocytes were incubated for 120 hours with 
or without 25 µM PLP rechallenge. A.) Cell metabolism and supernatant cytokine levels of B.) 
GM-CSF, C.) IFN-γ, D.) IL-10, E.) TNF-α, F.) IL-6, G.) IL-17, H.) IL-2, I.) IL-4, J.) IL-23, and 
K.) IL-15 were determined. (n= 5-6 per group, * p< 0.05 comparing different treatment groups, # 
p<0.05 for 25 µM PLP versus no PLP for the same treatment, ND indicates cytokine levels were 





Figure 6. Splenocytes were harvested on day 25 from EAE mice treated in vivo with components 
of co-delivery treatment, IFA with DEX + PLP.  Splenocytes were incubated for 120 hours with 
or without 25 µM PLP rechallenge. The cells were then stained with antibodies for CD3 (Alexa 
Fluor 488), CD19 (Alexa Fluor 647), and CD11c (Pacific Blue) and analyzed by flow cytometry.  
Cell populations were determined for A.) T-cells (CD3+), B.) Dendritic Cells (CD11c+), C.) B-
cells (CD19+) and D.) autoimmune associated B-cells (ABCs, CD19+CD11c+) as a percentage 
of the total cell population. E.) The percentage of CD11c+ cells out of the CD19+ cell population 
was also determined. F.) Gating for CD19+ B-cells is shown for both IFA and IFA with DEX + 
PLP, without antigen rechallenge. (n= 3-5 per group, * p< 0.05 comparing different treatment 
groups, # p<0.05 for 25 µM PLP versus no PLP for the same treatment, Black bars indicate 25 












Figure 7. Splenocytes were harvested on day 25 from EAE mice treated in vivo with components 
of co-delivery treatment, IFA with DEX + PLP, and were plated on wells coated with or without 
PLP antigen for 48 hours. Spots associated with B-cells producing PLP-specific antibodies were 
detected using HRP anti-IgG and TrueBlue stain, and imaged with a CTL ImmunoSpot 
Analyzer. A.) Representative wells both with and without antigen coating are shown.  B.) The 
number of spots per 1 million cells were compared for different treatment groups. (n= 5- 6 per 
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Antigen-specific immunotherapy (ASIT) has long been the cornerstone of vaccines, arguably 
one of the most important healthcare related-inventions.  The approach of vaccines, to utilize 
both antigen and immunomodulator (i.e., adjuvant), may hold the key to developing successful 
ASIT for autoimmunity.  As reviewed in chapter 1 and elaborated on in chapters 2, 3, and 4; 
promising results in experimental models of autoimmunity have demonstrated the efficacy of co-
delivery of autoantigen and immunomodulator as ASIT for autoimmunity.  With the positive 
results in these proof-of-concept studies there is increased hope that the combination of 
autoantigen and immunomodulator may hold the key to the creation of successful ASIT to treat, 
prevent, and possibly cure autoimmune disease. 
The B7 signaling pathway is a promising immunomodulator target for the treatment of EAE.  
In chapter 2, co-delivery of B7-targeted peptides and autoantigen with a novel vehicle, a soluble 
antigen array (SAgA) was found to suppress clinical disease symptoms of EAE as compared to 
the negative controls.  SAgAs co-delivering PLP autoantigen with each of the three different 
peptides targeting the B7 pathway or LABL, which targets ICAM-1, suppressed disease 
symptoms to a similar degree.  Although the clinical effects of the SAgAs were comparable, the 
cytokine responses in splenocytes harvested from the in vivo-treated mice demonstrated different 
immunological mechanisms.  Most notably the peptide mimic of CD28, B7AP, decreased levels 
of the pro-inflammatory cytokines GM-CSF and IL-2, while the other SAgA treatments did not.  
Another interesting finding was that the particulate nature of the SAgA with sF2, a peptide 
mimic of CTLA-4, did not change the ability to suppress EAE.  Combined, these results suggest 




with autoantigen, and different physical properties of the delivery vehicle (soluble or colloidal) 
can still be effective.  
In chapter 3, we demonstrated that splenocytes from EAE mice can be used as an antigen-
specific in vitro screening system for evaluating the immune response in an autoimmune model.  
EAE splenocytes demonstrated antigen-specific immune responses through rechallenge with 
PLP autoantigen, and therefore offered a mechanism by which to screen immunomodulators for 
their ability to skew the antigen-specific immune response towards tolerance.  Eleven small 
molecule immunomodulators were investigated for their potential to mitigate the antigen-specific 
immune response; however, only dexamethasone demonstrated tolerogenic responses. 
Dexamethasone was found to increase tolerogenic cytokines, decrease pro-inflammatory 
cytokines, and decreased CD3+ and CD3+CD4+ T-cell populations at a relevant dose.   
Chapter 4 elaborated on the work conducted in chapter 3, as dexamethasone was co-delivered 
with autoantigen (PLP) in vivo for the treatment of EAE. Using an IFA emulsion as a co-delivery 
vehicle, it was found that the controlled release of autoantigen was important for the suppression 
of clinical disease symptoms.  Co-delivery using IFA also shifted the immune response towards 
a humoral response by increasing B-cell populations. Additionally, analysis of the immune 
response via cytokines revealed that dexamethasone was important for shifting the immune 
response away from inflammation.  Overall, this data indicated that the co-delivery of PLP and 
dexamethasone with an oil-and-water emulsion is effective in treating a murine autoimmune 
model, and with further optimization the potential to be successful in humans. 
2. Future Work  
Although these studies demonstrate the potential of co-delivering autoantigen and 




should focus on optimizing each of the components in this therapy; the immunomodulator, the 
co-delivery vehicle, and possibly the autoantigen.  A better understanding of how each 
component acts alone and in combination will enhance our understanding of the mechanisms by 
which antigen-specific immune tolerance can be induced in combinational ASIT.  
Chapters 2 and 3 both focused primarily on optimization of the immunomodulator, and 
demonstrated that both B7-targeted peptides and small molecules such as dexamethasone may 
suppress autoimmunity.  Although both types of immunomodulators were effective, they act 
through very different mechanisms.  B7-targeted peptides are believed to bind proteins in the B7 
co-stimulatory pathway on the cell surface, whereas dexamethasone acts via an intracellular 
glucocorticoid receptor [1].  It is possible that the antigen-specific ex vivo screening system used 
in chapter 3 could be used to compare the tolerogenic effects of compounds that work 
extracellularly, such as the peptides described in chapter 2.  Many co-stimulatory pathways exist 
beyond the B7 pathway such as PD-1/PD-1L, CD40/CD40-L, ICOS/ICOS-L, and many others 
that could potentially be targeted by peptides [2].  A closer examination of these pathways and 
their potential to induce tolerance may lead to the discovery of an even more effective 
immunomodulatory peptide than those targeting the B7-pathway. Additionally, even for peptides 
that act on the same pathway, further investigation into their mechanisms of action may lead to 
more insight towards immunomodulator optimization.  For example, the sF2 peptide studied in 
chapter 2 was originally created to enhance T-cell proliferation and possibly exacerbate T-cell 
mediated diseases such as EAE [3].  The contradictory results found in chapter 2, that co-
delivery of this peptide with autoantigen suppresses EAE, should be further investigated to better 




The ex vivo screen of immunomodulators described in chapter 3 indicated that 
dexamethasone had the most tolerogenic potential; however, that screen may be further 
optimized to better examine the production of an antigen-specific regulatory immune response.  
Regulatory cell types, such as regulatory T-cells, B-cell, and DCs, are all important in the 
creation of antigen-specific tolerance that would be needed to reverse or cure autoimmunity.  
The presence of these cell types upon treatment with immunomodulators would lead to greater 
certainty of immunomodulator efficacy in vivo.  Regulatory T-cells (Tregs) are the most well 
studied regulatory cell population, and can be characterized by the surface markers CD3, CD4, 
and CD25 and by the intercellular protein FoxP3 [4, 5]. The presence of these cells even with the 
induction of immune tolerance is extremely low and often difficult to detect in a large splenocyte 
population, therefore the separation and concentration of the T-cell subpopulation before analysis 
may help enhance detection.  Both regulatory B-cells (Bregs) and tolerogenic DCs (tolDCs) are 
more difficult to detect and, due to their relatively recent discovery, there is not a consensus on 
the surface markers that designate these cell types [6, 7].  These cell types can be defined by the 
proteins or enzymes they produce; IL-10 for Bregs and indoleamine 2,3-dioxygenase (IDO) for 
tolDCs [6, 7]. Similar to with Tregs, the separation of subpopulations (B-cells and DCs) prior to 
analysis rather than analysis on all splenocytes may lead to greater ability to detect these 
populations.  
In addition to the immunomodulator, the co-delivery vehicle is essential for the production of 
an effective ASIT for autoimmunity.  As reviewed in chapter 1 several different vehicles have 
been studied for the co-delivery of immunomodulator and autoantigen, including microparticles, 
nanoparticles, liposomes, multivalent polymeric arrays, direct chemical linkage, and in chapter 4 




acid-based soluble antigen arrays (SAgAs) and the oil-in-water emulsion of incomplete freund’s 
adjuvant (IFA) can be efficacious at co-delivering autoantigen and immunomodulator for the 
treatment of EAE. Neither of these delivery systems has been approved for use in humans, 
therefore investigations of currently approved vehicles may allow for expedited creation of 
successful ASIT to treat human autoimmunity. Hyaluronic acid, the backbone of SAgAs, has 
been approved in many products on the market providing a clear path to SAgA approval [8].  On 
the other hand, IFA has been around for decades and although it has been used in clinical trials 
[9, 10] it has never been approved in a human therapeutic.  A major reason that it has not been 
approved is the propensity for IFA to cause severe inflammation or even granulomas at the site 
of injection [11].  Although IFA is not approved for human use, several oil-in-water emulsions 
are approved in the US or EU [12].  Additionally, several approved vaccine adjuvants are oil-in-
water emulsions such as MF59 and AS03[13].   
One interesting FDA-approved oil-based system is the tocopherol (tocol) family, including 
vitamin E and its derivatives.  Tocols have natural anti-oxidative and anti-inflammatory 
properties; therefore, a tocol-based emulsion may act as both a co-delivery vehicle and contribute 
to efficacy of an ASIT for autoimmunity [14].  Vitamin E and tocol esters such as α-tocopherol-
polyethyleneglycol-1000-succinate (TPGS) have been used in the creation of oil-in-water 
emulsions [14, 15]. Development of a vitamin E/ TPGS-based emulsion is currently underway in 
the Berkland laboratory, and future work with this delivery system is an exciting next step in the 
creation of ASIT for autoimmunity.   
Finally, the development of ASIT by combining autoantigen and immunomodulator can be 
applied to many different autoimmune diseases by changing the autoantigen.  In addition to MS, 




corresponding animal models [16, 17].  Future work in applying similar strategies for co-delivery 
of immunomodulator with autoantigens in other autoimmune diseases would bolster the amount 
of evidence in favor of this emerging trend in ASIT.  Overall, with continued research and 
optimization of the immunomodulator, co-delivery vehicle, and autoantigen, this combinational 
approach towards ASIT for autoimmunity may prove key in the treatment and even cure of 
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